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“If you build a model from a group of people who
are kind of similar to the current patient, you
might do better” Visweswaran 2012 [Sav12].
Abstract
Clinical trials are typically conducted over a population within a defined time period
in order to illuminate certain characteristics of a health issue or disease process. These
cross-sectional studies provide a snapshot of these disease processes over a large num-
ber of people but do not allow us to model the temporal nature of disease, which is
essential for modeling detailed prognostic predictions. Longitudinal studies, on the
other hand, are used to explore how these processes develop over time in a number
of people but can be expensive and time-consuming, and many studies only cover a
relatively small window within the disease process. This thesis describes the applica-
tion of intelligent data analysis techniques for extracting information from time series
generated by different diseases. The aim of this thesis is to identify intermediate stages
in a disease process and sub-categories of the disease exhibiting subtly different symp-
toms. It explores the use of a bootstrap technique that fits trajectories through the data
generating “pseudo time-series”. It addresses issues including: how clinical variables
interact as a disease progresses along the trajectories in the data; and how to automati-
cally identify different disease states along these trajectories, as well as the transitions
between them. The thesis documents how reliable time-series models can be creat-
ed from large amounts of historical cross-sectional data and a novel relabling/latent
variable approach has enabled the exploration of the temporal nature of disease pro-
gression. The proposed algorithms are tested extensively on simulated data and on
three real clinical datasets. Finally, a study is carried out to explore whether we can
“calibrate” pseudo time-series models with real longitudinal data in order to improve
them. Plausible directions for future research are discussed at the end of the thesis.
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Chapter 1
Introduction
1.1 Motivation
Clinical trials are typically conducted over a population within a defined time peri-
od in order to illuminate certain characteristics of a health issue or disease process.
These cross-sectional studies give us a snapshot of such disease processes over a large
number of people but do not allow us to model the temporal nature of disease. Lon-
gitudinal studies on the other hand, are used to explore how these processes develop
over time in a number of people but can be expensive and time-consuming, and of-
ten only cover a relatively small window within the disease process. Thus, there is
a need for effective computational techniques that can help people to gather informa-
tion from those unknown datasets in order to enhance the knowledge of the underly-
ing processes. In the biomedical domain, computational methods have become more
and more important for the evaluation and analysis of experimentally generated data.
There is already a large amount of work that explores data mining from cross-sectional
biomedical data in order to make predictions or understand the relationships between
1
2variables ([SSPGH06], [BZ08], [SS11]). Whilst some studies involve learning compu-
tational and statistical time-series models of progression from longitudinal data such as
([TVLGH05], [SL02], [HXW+10]), many datasets are cross-sectional and the time di-
mension is not measured, despite the inherently temporal nature of disease. This is due
to the expensive nature of these studies across an entire population. Disease progres-
sion can take different forms with different trajectories starting from healthy condition
and developing different symptoms, depending on the individual, before progressing
to advanced stages of a disease. Figure 1.1 shows two examples of disease progression
in breast cancer and glaucoma where possible trajectories (marked as arrows) denote
progression from healthy (light blue circles) to diseased stages (red crosses). Data has
been visualised using multi-dimensional scaling.
Expert clinicians generally believe that degenerative diseases are characterised by
a continuing deterioration of organs or tissues over time. However, this monotonic
increase in severity of symptoms is not always straightforward. The rate can vary in a
single patient during the course of their disease so that sometimes rapid deterioration is
observed while other times the symptoms of the sufferer may stabilise or even improve,
when medication is used. Interventions such as medication or surgery can make a huge
difference to quality of life and slow the process of disease progression, but they rarely
change the long term prognosis. The characteristic of many degenerative diseases is
therefore a general transition from healthy to early onset to advanced stages. There-
fore, clinicians need an ‘indicator’ to identify diseases and their progression for more
accurate medical prognosis. Medical prognosis (the prediction of the outcome of a dis-
ease) can be used to improve quality of life, slowing the tempo of disease progression
3Figure 1.1: Trends in progression of degenerative disease. An example from glaucoma
(top) and breast cancer (bottom).
as it can lead to early interventions. Furthermore, timely diagnosis can be extremely
beneficial as it can reduce the potential risk for patients. Notably disease onset may
take place before the first symptoms occur ([BSDP01], [BH05], [MMM+00]). Marcel
et al. [vGTL08] depicts an interaction to represent how the current patient state may
influence the next patient state (see as Figure 1.2). As Visweswaran said [Sav12] “if
you build a model from a group of people who are kind of similar to the current patient,
4you might do better”.
Figure 1.2: A clinical decision making in terms of a physician model and a patient
model.
The aim of this thesis is to learn disease trajectories as well as to identify inter-
mediate stages in the disease process by using a combination of bootstrapping, hidden
Markov models (HMMs) and unsupervised machine learning. Thus, this thesis focuss-
es on Machine learning [DRK04] methodologies for modelling disease progression,
dealing with a number of issues inherent with this. It uses a combination of bootstrap-
ping ([TGH10], [ET94]) and specialised hidden Markov models in order to model
disease and identify important regions in the disease trajectories. The approach of
relabeling trajectories has enabled the exploration of the temporal nature of disease
progression, and has been tested on both real and simulated biomedical data.
1.2 Research contributions
Main contributions of this research include:
• A full formal definition of a pseudo-time-series is derived, along with the asso-
ciated temporal bootstrap.
5• Identified of key regions in disease processes learnt from cross-sectional data.
An extension of the temporal bootstrap is explored, which can be used to identify
intermediate stages in a disease process and sub-categories of known diseases
with subtly different symptoms.
• Validation of the Pseudo-Times-Series model on a number of real-world biomed-
ical datasets. The reliable time-series models have been created from large
amounts of historical cross-sectional data from three very different diseases:
Glaucoma, Cancer and Parkinson’s disease using the temporal bootstrap tech-
nique and tested on real and simulated data.
• Exploration of the characteristics of the proposed algorithms, which is to demon-
strate the effectiveness of the proposed method, the performance of the approach
is explored on a number of simulated time-series generated from autoregressive
hidden Markov models (HMMs).
• The new approach to analyse, visualise and model checking, which is compared
with a clustering method for identifying key stages in disease progression based
on the ability to explain the underlying dynamics.
• Integration of cross-sectional and time-series data within the Pseudo-Times-
Series framework, which is includes exploring what degree pseudo time series
model can be improved and finding out how many or how few time-series data
is sufficient when cross-sectional data is abundant.
61.3 Organization of this thesis
Apart from this chapter, the remainder of this thesis is organised as follows:
• Chapter 2 presents the background knowledge and its role in disease progression
modelling for the research conducted for this thesis. It reviews the state of the art
methods, techniques and their performance. Gaps in the research area are also
identified, some of which will form the basis for the objectives of this study.
• Chapter 3 focuses on a variety of key concepts including hidden Markov models,
the temporal bootstrap developed using different methods and algorithms rele-
vant to this research. The process of application of the new relabelling technique
for extracting key stages in disease from both cross-sectional and longitudinal
studies to build reliable models of disease progression, is demonstrated and ex-
plained. Finally, the real-world clinical datasets are introduced.
• In Chapter 4, results produced by using the proposed relabelling algorithm on
the three different clinical datasets are presented and analysed. These results are
used for exploring disease trajectories as well as simulated data. A comparison
of the trajectories within a medical context is discussed.
• Chapter 5 explores the calibration of models learnt from cross-sectional data, the
results using small samples of longitudinal data are presented.
• Chapter 6 summarises all key achievements and contributions towards the iden-
tified aim and objectives of this research project. Research limitations for further
research and development in this area of research are discussed.
Chapter 2
Literature Review
This chapter reviews previous and current studies concerning the application of ma-
chine learning in medicine. Firstly, the nature of data associated with clinical trials
is discussed with a focus on cross-sectional and longitudinal studies. This is to gain
an insight into the advantages and disadvantages of these commonly used approach-
es when building predictive models. Next, different state-of-the-art machine learning
techniques are introduced within a clinical data perspective discussing examples of
their use and how the different techniques perform at predicting and understanding
disease outcome. This review covers the subjects of machine learning, time-series
modelling, classification and clustering using different techniques common in biomed-
ical data analysis. Through this survey, gaps in this research area are identified, in par-
ticular concerning the weaknesses of cross-sectional and longitudinal data, on which
the objectives for this thesis are centred.
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82.1 Clinical Trials
Clinical trials are sets of tests taken from a wide range of medical areas that are typi-
cally conducted over a population, within a defined time period, in order to illuminate
certain characteristics of a health issue or disease process. They can vary in size con-
siderably. Clinical trials can be effectively used for identifying responses to interven-
tions such as patients’ response to drugs, the side effects of drugs and their concurrent
diseases [SMB+03]. They can also be used to explore the variation in disease symp-
toms by applying clinical metrics to a large population exhibiting varying symptoms
from the healthy through to the advanced disease stages, such as the use of multiple
endpoints in interim analyses for disease treatments [SNA87].
A typical example of clinical data that is commonly used in large-scale clinical
trials is the data obtained by Heidelberg Retinal Tomography (HRT) [GHFH00] which
consists of measurements associated with the three dimensional shapes of the optic
nerve head. Another test which will be used later in this thesis measures vocal im-
pairment as early indicators for the onset of the Parkinson’s disease (PD). A number
of voice measurements have drawn significant attention for detecting and tracking the
progression of symptoms of PD [LMR+07]. The final dataset that is used in this study
concerns cancer [RSMJ85], [CYYK05], [PWM+99]. These studies are often based
upon tumour examinations where characteristics of tumours are measured to explore
the effect of a medical treatment.
Whilst many clinical trials are cross-sectional where only one measurement is made
per individual, some involve longitudinal studies where a (relatively smaller) number
of people are followed over a period of time. Albert [Alb99] discussed five different
9clinical trials where the primary outcome is observed over time, allowing longitudinal
data analysis. This study highlights that sequential monitoring is an important issue in
clinical trials identifying sequence of events in individuals directly.
It is also worth noting that clinical trial data is often used in combination with
historical data in order to improve the statistical validity of the conclusions. For ex-
ample, randomised clinical trials with 6-12 months of clinical follow-up were used in
[MLP+04] comparing different clinical interventions (here the insertion of a small tube
- stent - into arteries for introducing drugs in a controlled manner). The study involved
a large scale meta-analysis of 11 trials in order to quantify more accurately their effect
on blood vessel narrowing (restenosis).
2.2 Cross-sectional and Longitudinal Studies
Cross-sectional studies are methods of clinical observation that only record informa-
tion (such as clinical test results and demographics) across a sample of the population
from subjects without modifying the environment. They do not consider past or future
behaviour [Wor09] (a particular disease process but without any measurement of pro-
gression of the process over time), and all measurements on each subject are made at a
single point in time [Man03]. For example, one may choose to measure insulin levels
in diabetes patients across two age groups, over 40 and under 40, and compare them
to insulin levels among controls. However, they do not normally consider the past or
future insulin levels of diabetes patients. Cross-sectional studies can also be used to
create subgroups for family diseases, for example gender or body mass index (BMI).
A main advantage of cross-sectional studies is that they can compare many different
10
variables at the same time with fewer resources. They typically include people who
are healthy as well as people at all stages of a particular disease process (if the sample
is large enough) in the analysis. They are also relatively cheap and simple to perform
[Man03], [Wor09], [JLTL81] in comparison to longitudinal studies. Cross-sectional
studies give us a ‘snapshot’ of disease processes over a large number of people but do
not allow us to model the temporal nature of disease, because the time dimension is not
captured. For example, subgroups may exist that depend on temporal behaviour. Mann
[Man03] indicates that “it is better to study a cross-sectional sample of patients who
already have the disease” by employing longitudinal studies. This does however mean
that many patients who are displaying early signs of disease onset may be missed.
Longitudinal studies [Dig02] are another observational approach that is used to
explore how disease processes develop over time in a number of people. In clinical
trials, longitudinal data are collected for three reasons [Alb99]: first, to obtain a more
precise estimate of the outcome and hence the treatment effect; Second, to monitor
clinical variables at a particular time; third, to evaluate the effect of treatment over
time. Clinical test results are recorded, often without manipulating the study envi-
ronment. Although the trial has the potential to provide definite information about
“cause-end-effect” relationships, it may require monitoring the same subjects, over a
long period of time [Wor09]. The results of multiple tests are recorded, generating
Multivariate Time-Series data. This is common for patients who have high risk indica-
tors of disease where they are monitored regularly prior to diagnosis. Cross-sectional
studies cannot serve this purpose. For example, it may be chosen to look at the change
in insulin levels among men over 40 who have been smoking for a period of more than
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20 years. The longitudinal study design would account for insulin levels at the onset
of a smoking regime and as the smoking behaviour continued over time. The advan-
tages of a longitudinal study are that researchers can distinguish the individual level
changes in the characteristics of the target subject [Dig02], and capture the temporal
details of the disease progression beyond a single moment in time [Wor09]. However,
the data is often limited in terms of the cohort size, due to the expensive nature of the
studies. Albert [Alb99] proposed that “extensions of multiple endpoint methodology
to the analysis of longitudinal data is another interesting area”. For example, where
similar early symptoms may end up following one of a number of potential disease
trajectories. Such studies can be expensive and time-consuming, and many only cover
a relatively small window within the disease process [YSA13].
Regardless of the advantages and disadvantages of cross-sectional and longitudinal
studies, it seems that both have weaknesses when used on their own. Hence, there is
an on-going effort to combine and use both approaches in conjunction ([LMH+88],
[AZP06], [RPK+03], [AFS+04]). Cross-sectional studies are the best way to deter-
mine prevalence and variation in a wide population but do not provide an explana-
tion for the findings [WDL+90], while longitudinal studies could provide “cause-end-
effect” relationships but only under limited samples.
2.3 Machine Learning in Medicine
Machine learning (ML) [MBK98], [Mit97] belongs to the field of artificial intelligence
[LCS+06], [Kon01]. It is used to extract useful and meaningful information from
complex data. The aim of ML is to provide computational methods to learn from
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data. This can be anything from the identification of patterns of similar behaviour to
complex mappings between symptoms and diagnoses.
There are two major types of machine learning: supervised and unsupervised learn-
ing. Supervised learning is used to classify datasets by learning a mapping between
the data (usually the results of some clinical test) and some predefined class label
(representing some disease outcome) determined by an expert in the field. It involves
learning a function from a set of training data and using this to predict the class for
new input data (the test set). In contrast, unsupervised learning involves learning from
data that has no class information by identifying similar data regions (or clusters). For
example, it can be used to identify patients with similar symptoms.
Computational methods are becoming more and more important for the evaluation
and analysis of experimental data, assisting us to extract useful information in as an
automated as possible manner, especially when there are 98 large amounts of data. M-
L has been widely applied in many areas: a natural language system was successfully
developed for various tasks involving text processing and an automated script for data
collection [HDA01]; Larranaga et al. [LCS+06] used ML techniques to deal with gene
identification problems. ML is also used to make predictions for experiments, such as
Chen and Xu[CX04] applied ML for protein dispensability prediction. Furthermore,
ML is often used to find the relationships between observed variables within datasets
in a medical context, improving the efficiency and quality of medical decision making
[KKG+99] [MP01a]. A major research effort in this field is to automatically classify
disease [Org] and predict future outcomes for patients [Sav12]. Clinicians may use
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ML methods to generate new hypotheses to enhance their basic diagnostic and prog-
nostic processes [MP01a], [BGP99], [Jan99], [RRL99]. Based on the number of ML
publications and the increasing use of ML techniques in medicine, it appears that ML
will play an ever more important role in clinical medicine. The next section documents
some examples of successful machine learning applications in medicine.
2.3.1 Analysis of Time-series Focusing on Clinical Data
Time-series can be simply defined as a sequence of data points that is character-
ized by its continuous nature. This kind of data is widely used in various domains,
such as econometrics, finance, earthquake prediction, weather forecasting, as well as
biomedicine (in longitudinal data analysis). In general, time-series analysis is applied
to experimental data measured over a period of time, in order to extract meaningful
information from uncertain data, and to predict future values of variables ([LAR03],
[Cha96]). Sometimes, data is also available on several related variables of interest,
which can be defined as Multivariate Time-series (MTS) (more details in Section 3.1).
MTS can be used to study the dynamic relationships between variables over time in
order to predict the progression of degenerative diseases, such as Parkinson’s disease,
glaucoma or cancer. MTS often give better predictions than univariate time-series
models. Specialists in medicine are interested in how a disease progresses across the
time-series. Clearly these trends will depend upon a number of factors such as which
clinical variables are selected, how much data there is available in the sample, and
whether the disease process is generally monotonic. According to [Fu11]: the way to
represent the time series data is the fundamental problem in the context of time series
data mining. In order to infer the process of disease progression, an appropriate use of
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a modelling approach is needed.
A time-series model can be built when time stamps (discrete or continuous) are
available. These models can be used to try and predict future values of the data or the
disease outcome. Tiao et al. [CMJ98] suggest two reasons for analyzing and modelling
time-series data: first, to understand the dynamic relationships among variables (one
series may lead the others), and second, to improve accuracy of forecasts. Linden
et al. [LAR03] listed three basic steps for the development of a time-series model:
(1) graphing the data; (2) choosing the appropriate model and fitting the data; (3)
evaluating the model. There are a number of popular approaches to modelling time-
series. For example, the Box-Jenkins method [BJR13] is known as the Autoregressive
Integrated Moving Average (ARIMA) as it combines the autoregressive and moving
average processes to model past observations and errors. It handles trends and cycles
through differencing the data. The approach is attractive due to its ability to capture
a diverse set of time-series behaviour. However, as a result of its flexibility it can risk
overfitting data. Another very common time-series modelling approach is the hidden
Markov model (HMM) [Rab89] (See section 3.4.1 for more details). It is a popular
model for modelling sequential and time-series data which can deal with uncertainty
and noise. A correct model is essential to predict future values based on previous
observations and this can include forecasting, regression analysis and classification.
Regression techniques aim to fit a model (linear or polynomial) through the data where
time is used to predict the rate of change in some set of clinical variables [VFH97].
Linear regression attempts to find a straight line that best ‘fits’ the data. See Figure 2.1
for an example.
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Figure 2.1: The example of clinical linear regression. Adapted from [KFD+10].
As well as classification methods can be regarded as types of data mining approach-
es to modelling time-series data in medicine (see section 2.3.2), however, care must be
taken as observations are not independent of one another (symptoms at time t are typ-
ically dependent on the symptoms at t − 1). Previous observations play an important
role in time-series analysis, since they can be used as basis for future behaviour pre-
diction [LAR03].
There has been some preliminary work conducted in an effort to create reliable
time-series models from large amounts of historical cross-sectional data. For exam-
ple, Broman et al. [BQW+08] attempts to estimate the rate of glaucoma progression
from cross-sectional studies by using the mean damage in the eye and the mean age of
disease onset. In [TGH10], a combination of distance metrics, graph theoretical opera-
tions and resampling is used to build trajectories through the dataspace. Bellazzi et al.
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[BLM+99] combined time-series analysis and temporal abstraction techniques to the
analysis of time-series data of Blood Glucose Levels, from insulin dependent diabetes
patients. Diggle[Dig02] explored three certain longitudinal data sets from the biomed-
ical domain, which present the challenges for analysis: First, in HIV, an immune cell
called CD4+ is attacked by the virus, and its numbers decrease with time following
infection, thus it can be used to monitor disease progression; Second, a three-period
crossover trial of primary dysmenorrhoea produced data was used to examine the ef-
fectiveness of pain killers; the last, a dataset from a clinical trial of drug therapies for
schizophrenia. Other studies involve learning computational and statistical time-series
models of progression from longitudinal data ([TVLGH05], [SL02], [HXW+10]).
In conclusion, time-series analysis methods are important tools for analysis of med-
ical data to anticipate disease [RM03]. Time-series analysis lies in the heart of the work
presented in this thesis and we will explore probabilistic models like hidden Markov
models (HMMs) in more detail in Chapter 3.
2.3.2 Intelligent Data Analysis in Medicine: Classification Meth-
ods
A set of data with known structure can be divided into classes. For example, if in-
formation about some labelling of the data is available then supervised classification
algorithms can induce the rules from the data [LCS+06] in order to predict new cas-
es. More formally, classification tasks involve learning a mapping from a vector of
measurements to a categorical variable. The variable to be predicted (the class vari-
able), takes values in the set C = {c1, ..., cm}. The observed variables d1, ..., di are
referred to as the features. Classification takes are becoming increasingly popular due
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to dramatic increases in the availability of large collections of medical data [PSS+09],
[ZL10], [VPR+07]. Any improvements in prediction will result in better medical de-
cision making which, can be very valuable for diagnosing future patients [VAH+10],
[RKM09]. For example ML classification was explored in the study of breast can-
cer [BHK]. Here, Bontempi and Haibe-Kains used classification techniques to divide
breast cancer patients into groups for different clinical therapy. Classification was
based on tumours with similar histopathological appearance. The study examined var-
ious clinical sources and responses to therapy. The results revealed that biologists often
failed to accurately classify breast cancer due to tumour metastasis, thus highlighting
the ability of ML methods to assist clinical experts in making diagnoses. One other
popular biomedical application of ML classification concerns the use gene expression
data to classify disease. Many databases containing gene expression information for
patients can be used to classify cohorts with different diseases from control group-
s. For example, in a study of tumours [vVDVDV+02], which applied classification
techniques to identify a gene expression signature. This is known as feature selection
where a small number of variables are identified as most informative in a classification
task.
There are a number of approaches and methodologies used in classification in the
clinical data analysis area. The main ones are discussed in the following section (based
on a combination of predictive performance and their ability to explain the underlying
relationships in a dataset): Bayesian Networks (BNs), Naı¨ve Bayes (NBs), Neural Net-
works (NNs) and Decision Tree (DTree).
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2.3.2.1 Bayesian Networks in Medicine
Bayesian Networks (BNs) (See Figure 2.2) are probabilistic graph-based models that
represent the probabilistic interdependencies between variables. They are simple, com-
monly used and less prone to overfitting the data as they are biased towards simple
networks (the data source can be stationary and not vary with time). BNs typically
consist of two components: a directed acyclic graph (DAG) with nodes representing
any variance of variables that exists in the real world, and a set of conditional interde-
pendencies associated with each node (see Figure 3.2).
The networks can be used to represent the network qualitatively and quantitative-
ly using a graphical structure involving nodes that have an associated conditional
probability distribution. BNs can also be used to answer probabilistic queries about
networks. BNs have become more and more popular, being used for the computa-
tional modelling of knowledge in many areas such as bioinformatics, medicine, and
decision-making systems. They are particularly powerful in transparently modelling
the relationship between variables and capturing the uncertainty in knowledge and data
[LCS+06].
One of the key advantages of Bayesian networks is their ability to integrate data
with human expertise. This can be achieved using the notion of an informative pri-
or [CS00], where a model is constructed and then updated when more data becomes
available using Bayesian updating techniques, resulting in a posterior model.
Microarray data analysis methods often fail to correctly deal with uncertainty, thus
BNs have advantages for analyzing gene microarray data, especially for un-normalised
cDNA microarray data [Wil07]. BN classifiers can also be used to analyze differential
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gene expression, to provide useful information about biological pathways [Slo02].
BNs not only work on very different types of data but they have also proven very
popular for modelling combinations of different types of data in a single model (such as
gene expression and clinical data). For example, Gevaert et al. [GDST+06] learnt BNs
on breast cancer patients data treating clinical and microarray data on an equal footing.
Visweswaran et al. showed that patient-specific models could be improved through the
use of a Bayesian model. Elsewhere, BNs were applied to the diagnosis and prognosis
of first cerebral paroxysm [ZLNRP99]. In an effort to avoid a “wrong blood in tube”
error (‘a specimen of blood collected on Patient A, but for which the accompanying
requisition and label is for Patient B’), which can kill people more often than another
accidents or diseases, a BN was used to predict the mismatches of Glucose and HbA1c
in two experiments [DS10].
Figure 2.2: Example architecture of a Bayesian Network. The diagram adopted from
[Coo99], which is hypothetically about the medical domain with 5 variables.
Dynamic Bayesian Networks (DBNs) (See Figure 2.3 [PdKJ+10]) can be defined
as a special case of Bayesian Networks that can model sequential data or time-series
[FGW99]. They are known as time-series analysis, which consist of a set of observa-
tions from the data source (a sequence of variables) dynamically changing over time.
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Unlike BNs, DBNs can provide direct mechanisms for representing temporal depen-
dencies. Therefore, DBNs enable users to update the system and also predict further
events. More recently, they have become popular for modelling disease [TVLGH05]
and are useful as both prognostic and diagnostic tools. This is due to the fact that they
explicitly model temporal (dynamic) and non-temporal relationships among different
variables in the real world and are flexible enough to model latent variables.
Several applications of DBNs have been proposed in medicine. For example, in
monitoring the treatment of renal failure patients [CCC05], BNs are implemented to
represent relationships between Hydration and Dialysis Sessions on Dry Weight. DB-
Ns are used to model dynamic processes of the treatment in order to explore whether
past events have an effect on the present state of the patient. Watt et al. [WB08]
used DBNs to help predict early presence of Osteoarthritis (a knee disease that can
cause knee pain, disability and decreased bone mass) and analyse the progression of
the condition over time. Van Gerven et al. [vGTL08] used three individual patients´
case to construct DBNs for prognosis. They demonstrated that DBNs not only serve
for modelling disease progression, but can also identify the effect of treatment and the
development of complications. In [CGHCT12] a form of DBN, that clusters sections
of time series whilst simultaneously learning DBN structure and parameters, was used
to model glaucoma progression. Furthermore, DBNs are also used to model Neuronal
Interactivity for brain activation patterns [ZSAK+05], and to optimise treatment in
intensive care unit (ICU) [CVDGV+09].
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Figure 2.3: A Dynamic Bayesian Networks (Predicting Attacks). Possible transitions
between variables at the same time-slice. The Figure shows an example of DBN with
number of variables over time lags where each node represents a variable at a certain
time slice and each link represents a conditional dependency between organ systems.
Adapted from [PdKJ+10].
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It is a non-trivial problem to create DBNs from data. Table 2.1 lists four different
stratums of creating DBNs. ‘Complete data’ means all variables are known, while ‘in-
complete data’ means some variables cannot be measured in some situations, referred
to as missing variables. ‘Unknown structure and full observability’ refers to finding
a way to learn the structure of DBNs from observable data. In this thesis, we focus
on the ‘unknown structure and partial observability’ because some variables cannot be
observed in the real world and it is hard to distinguish the structure when learning DB-
Ns from real data. The EM algorithm (see 3.4.1 for more details) is a powerful method
to tackle this problem, and it can improve the likelihood of the data given the model.
Structure/Observability Method
Known/Full (complete data) Simple statistics
Known/Partial (incomplete data) EM or gradient ascent
Unknown/Full Search through model space
Unknown/Partial Structural EM
Table 2.1: Methods for creating DBNs structure and determining their parameters.
Adapted from [MP01b].
2.3.2.2 The Naı¨ve Bayes in Medicine
Naı¨ve Bayes (NBs) (See Figure 2.4) is a simple probabilistic classifier using Bayes the-
orem with strong naı¨ve independence assumptions [Zha04], where no hidden attributes
influence the prediction process [GP95]. This classifier requires a small amount of
training data to estimate the parameters necessary for classification, and is fast to train.
It is also called an optimum classifier, because this classifier can minimize the cost of
total misclassification. It has been successfully used in many applications, such as the
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Rainbow program which employs a NBs classifier to perform statistical text classifi-
cation [A.K96]. Yousef et al. [YJK+07] used the Rainbow program to train the NBs
classifier for microRNA target gene prediction. Palaniappan et al. [PA08] used NBs
along with another two predictive models, in order to discover the hidden patterns and
relationships between different medical profiles and to develop an intelligent predic-
tion system for heart disease. Although the NBs classifier is generally an effective
and versatile classification approach, sometimes false predictions may occur because
NBs can not gives appropriate descriptions for the relationships between the variables
and the outcomes. The positional independence assumption of the NBs makes the
computation of the joint probability value easier at the expense of the accuracy or the
underlying reality (it is the strength as well as the weakness [PLV02]). NBs are the
simplest form of Bayesian Network, too simple to model complex domains, where all
attributes are independent. Therefore, only the variances of the variables for each class
need to be determined.
Figure 2.4: Example architecture of The Naı¨ve Bayes. In the diagram, theQ represents
a parent of theA,B,C,D andE. It is assumed that all the variables are independent for
a given class Q. Given the values of A,B,C,D and E we can estimate the probability
of the class, Q using the Bayes rule.
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2.3.2.3 Neural Networks in Medicine
Neural Networks (NNs) (see Figure 2.5 [Hel13]) constitute a set of machine learn-
ing methodologies inspired by the structure of neurons in the brain [ZB08]. They are
good at dealing with the complexity of experimentally generated data, which consists
of nodes (neurons) that receive, process and transmit signals. The perceptron is the
simplest neural network structure. It has the ability to learn from examples, that is a
distinctive aspect of NNs over other classifiers. It contains two layers: the first lay-
er is input layer and the second layer is the output layer. Both layers can have many
nodes and units. NNs have the ability to give straightforward theoretical prediction-
s on DNA sequence level, protein sequence level and protein structure level [BA06].
Odewahn et al. [OSP+92] pointed out that NNs are good at managing problems with
a large amount of parameters, and at classifying objects distributed in complex high-
dimensional space. For example, Nagl [Nag01] successfully applied NNs in a protein
study, which were used to analyse the emergence of drug resistance in HIV-1 (human
immunodeficiency virus 1). In another case, Lisboa and Taktak [LT06] explored the
benefits of NNs as decision making tools (diagnosis and prognosis). Using 396 clinical
trials (cancer), most of the studies showed an increase in benefit to healthcare provi-
sion. Furthermore, NNs are used to estimate medical outcomes and resource utilization
in intensive care unit environments (ICUs)[FEST01].
NNs also have their limitations. For example, Satish and Gururaj [SG93]
demonstrated the limitations of the NNs with a single layer NNs. The NNs could only
classify linearly separable signals, and proved inadequate to achieve the required tasks.
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Multilayer Neural Networks (MNNs), also known as the Multilayer Perceptron,
have layers between the input and output layers. A MNN is a fully connected network
where all nodes from one layer are connected to the next layer and can be extend-
ed to any number of hidden and output layers. This type of NN can learn complex
functions. The MNN deals with non-linearly classifiable data by employing hidden
layers (neurons are not directly connected to the output) and essentially linking nu-
merous perceptrons (which are the individual neural network units) together. The big
advantage of MNNs lies in the fact that all nodes from one layer are fully connected to
the next layer and can be extended to any number of hidden and output layers. Back
propagation is the main algorithm utilised in multilayer neural networks. The main
drawback to back propagation is that it is susceptible to overfitting the training data at
the cost of decreasing generalization accuracy over other new data [Mit97]. In the med-
ical domain, some authors ([JAGRRJ+03], [FWIB95], [Kiy11] have modelled systems
for prognosis in breast cancer patients using MNNs. Chen et al. [CLKW97] imple-
mented MNNs for the purpose of designing the dynamics of the mean arterial blood
pressure system, in order to meet specified clinical constraints. Yan et al. [YJZ+06]
developed a decision support system to support the diagnosis of heart diseases based
on MNNs. In order to achieve high diagnosis accuracy they used five different kinds of
heart diseases from 352 clinical records to train and test the system. Li et al. [LLCJ00]
demonstrated MNNs are appropriate for non-linear medical decision support system
in traumatic brain injury (cause of death and disability that include falls or vehicle
accidents). MNNs have also been used to classify low back pain [VCT+00].
Whilst, artificial neural networks (See Figure 2.5 for an example) have good
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predictive performance, they are quite slow in both the training phase and application
phases [BZ08], compared to simpler modelling methods such as BNs. They are also
very prone to overfitting, where a classifier has focussed on a small area of data that
may be irrelevant to the classification task. This is often due to too many parameters.
Figure 2.5: Example architecture of a Simple Neural Network. In the diagram, the
inputs are separately transformed into a 3-dimensional vector hidden layer, which is
finally transformed into the Drug (forward propagation). The output ‘Drug’ depends
upon the random variables of the vector hidden layer, which depends upon the random
variable inputs (back propagation). These two stages are independent of each other.
Adapted from [Hel13].
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2.3.2.4 Decision Tree in Medicine
A Decision Tree (see Figure 2.6 [WLH+09]) is a well documented machine learning
method for classification, which is very easy to understand and widely used in clas-
sification problems, such as disease classification[Mit97]. In the traditional decision
tree, the nodes represent decisions, arcs represent possible answers, and terminal nodes
represent classification. The root node is located at the top of the tree and the tree is
traversed starting at the root node. At each decision node, the different links represent
the possible answers. This process is repeated from a root node until a terminal node
(leaf node) is reached, where a class is allocated ([LKZ00], [BB01]). Links must be
mutually distinct and exhaustive. In other words one and only one link will be fol-
lowed [LCS+06]. Thus, all the decision nodes are working together, following along
the path of the decision tree from root node to the leaf nodes [BZ08]. However when
the training set is small, the terminal node of a decision tree is defined by chance if no
one class can be identified clearly [Ber03].
The Alternating Decision Tree (ADTree) is a special case of a decision tree. It is
a majority-weighted vote over very simple prediction rules, which deploys a type of
machine learning method based on boosting for classification [FM99]. The ADTree
is smaller and easier to interpret than other classifiers. The structure of an ADTree is
similar to the standard decision tree, but can sometimes achieve better performance.
One special feature of ADTree classifiers is that they give the classification margin
as a measure of confidence. For example, Takada et al. [TSN+12] used an ADTree
as a prediction model for predicting axillary lymph node metastasis in breast cancer
patients (the node is examined for diagnosis of breast cancer). Using various clinical
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Figure 2.6: Example architecture of a Decision Tree, which is being used for deter-
mining disease progression based on the number of capillaries classified. From the
diagram, it can be seen that there might be 4 types of symptoms that have been classi-
fied. Adapted from [WLH+09].
variables, they were able to achieve 95% accuracy on all the resulting values. The
ADTree based approach has also been implemented for prediction of dengue fever
(an infectious tropical disease that is transmitted by mosquito) with high accuracy
[Kum13]. One special feature of ADTree classifiers is that they give the classification
margin as a measure of confidence and each partition can be split multiple times. “The
alternating tree maps each instance to a real valued prediction with the sum of the
predictions of the base rules in its set. The classification of an instance is the sign
of the prediction” [FM99]. ADTree has been used to predict survival of heart failure
patients, by classifying them into groups that are expected to survive over a certain
period of time or not [JKD13]. Experiments on a collection of datasets taken from
the UCI machine-learning repository [NHBM], showed that the ADTree method is
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efficient with small data sets, and is much easier to interpret than a standard decision
tree with the same number of decision nodes.
Although decision trees are effective at solving classification problems, they also
have limitations given that the typical top-down partitioning through a greedy split
evaluation may result in quality loss [BBdC+09] and may be sub-optimal. Classifiers
such as decision trees, NBs and MNNs clearly have a role in medical informatics and
in particular modelling disease when a diagnosis has been identified within a dataset.
We will explore how the ‘class data’ (whether data has been labelled as healthy or
diseased) can be used to build trajectories in the chapter 3.
2.3.3 Application of Machine Learning Methods to Medical Data
Analysis: Clustering Methods
Clustering is a common technique for data analysis. It is an unsupervised machine
learning method which deals with finding meaningful groups (the members are similar
in some way) in a collection of unlabeled data. More formally, clustering can be de-
fined as by given a representation ofN objectsD = d1, ..., dn, find k clustersC1, ..., Ck
based on a measure of similarity. Each data point di is assigned to a unique cluster Ck.
It has been extensively used in a variety of fields, including: marketing (finding groups
of customers [HTO07]), biology (grouping gene expression data [CTC+05]), medicine
(evaluation of data from clinical trial [FSN+00]) etc.. An important component of a
clustering algorithm is the distance measure or similarity measure between data points.
Data points that are close to each other according to a given metric or that have similar
descriptive concepts belong to the same cluster. The efficiency of clustering algorithms
and their application in a wide range of scientific fields is an area of active research.
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The four most popular clustering algorithms for high dimensional data used in the
biomedical domain are:
• K-means which is used to cluster the observations into k clusters, based upon
distance of observations to k centroids (the allocation of data points and the cen-
troids are iteratively updated). In gene expression data analysis [Slo02]. Bushel
et al. [BWG07] explored an extension of the k-means algorithm, called mode
k-prototypes for clustering heart disease samples.
• Fuzzy C-means clustering, where observations can belong to more than one clus-
ter (centroid) with different degrees. It has been implemented for classification
of oral cancer cell data [WGO03]). A modified fuzzy c-means algorithm has
been utilised for bias field estimation and segmentation of magnetic resonance
imaging data [AYM+02].
• Hierarchical clustering which has two approaches: the first is ‘bottom up’, which
starts at each observation, merging together data points or clusters, and then
moves up the hierarchy; the other is ‘top down’, starting with one large cluster,
then moving down the hierarchy, splitting clusters until all data is in its own
cluster. Veer et al. [vVDVDV+02] implemented hierarchical clustering for the
purpose of clustering tumours on the basis of their similarities, to predict clinical
outcome of breast cancer.
• Gaussian Mixture clustering, which uses a mixture model to represent the prob-
ability distribution of observations, and therefore cluster the data. For example,
Gaussian Mixture Model-based segmentation has been applied in lung tumor
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clinical studies [APMP07].
Despite the fact that the extensive research has been conducted to extend and im-
prove clustering algorithms, they still have a number of limitations. Karypis et al.
indicated that many advanced algorithms do not follow a preconceived model because
they cannot faultlessly deal with highly variable clusters [KHK99]. For example, the
K-means algorithm does not perform well with high dimensional data, when clusters
in the data have different sizes, shapes and densities such as commonly in many clini-
cal datasets. Hierarchial clustering also has limitations due to problems with defining
a distance metric in high dimensional data [ESK02].
Clustering is clearly relevant to identifying regions of interest in a disease pro-
cess. Therefore chapter 3 of this thesis will examine a method that involves using the
Expectation Maximisation (EM) algorithm.
2.4 Summary
This chapter reviewed previous and current research work in the field of machine learn-
ing for biomedical data analysis. It discussed subjects including clinical trials, cross-
sectional and longitudinal studies, machine learning, classification methods, clustering
methods and time-series modelling. Four major models of classification and clustering
were examined in a biomedical context.
The major conclusions arising from this review are:
(1) Cross-sectional studies do not allow us to model the temporal nature of disease
and the time dimension is not captured as observations are taken at only one fixed point
in time;
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(2) Longitudinal studies are expensive due to their nature as individuals must be
followed over time. In addition many studies only cover a relatively small window
within the disease process, often missing the vital early stages.
(3) Building sequences through cross-sectional data is relatively unexplored,
though Broman et al. [BQW+08] have recently investigated estimating rates of pro-
gression in glaucoma from cross-sectional studies and Tucker [TGH10] has explored
building trajectories through cross-sectional data - which is to be further explored in
Chapter 4.
(4) Multiple endpoints were highlighted as an important issue (Albert [Alb99])
which again are relatively unexplored and will be further investigated in Chapter 4.
(5) Clustering data can help in understanding subcategories of disease such as d-
ifferent subpopulation of cancer sufferers as well as identifying important stages in a
disease process (where data points in a series are clustered - for example into early,
mid and late stages).
Based on the points above, the research in this thesis focuses on the use of
sequence-building through cross-sectional data (including trajectories with multiple
endpoints) by formalising and extending the pseudo time-series introduced by Tucker
[TGH10]. It deals with clustering trajectories to identify important stages in a disease;
and exploring how cross-sectional and longitudinal data can both be used to build more
reliable models. The details of the methods undertaken, along with some preliminary
results, are presented in the next chapter.
Chapter 3
Identifying Key Stages in a Disease
Process from Cross-Sectional Data -
Methods and Algorithms
This chapter deals with the different methods undertaken in this thesis as well as a
formal definition of a Pseudo-Time-Series (PTS) is introduced for the first time. Mul-
tivariate Time-Series (MTS) modelling is explored in detail. The Floyd-Warshall al-
gorithm [Flo62], a well-established algorithm that used to find the shortest path in a
weighted graph (and therefore trajectories through data) will be described. In order
to build more robust time-series models, the concept of a pseudo-time-series is in-
troduced based upon the work in [TGH10], and a formal definition of this is further
derived (as published in [LST12]). The details of the temporal bootstrap are illustrated
with respect to this new formal definition. This is followed by a description of the per-
formance of three typical models that are used for modelling time-series data: hidden
Markov models, Bayesian Networks and Dynamic Bayesian Networks. Finally, a new
algorithm for identifying key stages in pseudo-time-series is introduced (as published
in [LT10]) which is focussed on in this thesis.
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3.1 Multivariate Time-series Modelling with Pseudo
Time-Series
A pseudo time-series is a sequence of observations measured over time, which aims to
build multiple trajectories through cross-sectional data in order to approximate genuine
longitudinal data. Building pseudo time-series involves plotting multiple trajectories
through cross-sectional data based upon distances between data points, using prior
knowledge of healthy and disease states to guide the trajectories. These trajectories
can then be used to build approximate temporal models to make forecasts. However,
models that can exploit multivariate time-series data can be very challenging to learn
reliably. The formal definition of MTS is the following.
Definition: Let a dataset D be defined as a real valued matrix where m (rows) is
the number of samples (here patients) - and n (columns) is the number of variables
in the clinical test data. We define D(i) as the ith row of matrix D. The vector C =
[c1, c2, ..., cm] represents defined classes, where each ci ∈ {0, 1} corresponds to the
sample i, ci = 0 represents that sample i is a healthy case, and ci = 1 represents that
sample i corresponds to a diseased case. These classifications are based upon expert
diagnoses.
A time-series is defined as a real valued T (row) by n (column) matrix where each
row corresponds to an observation measured over T time points. If T (i) was observed
before T (j) then i < j.
We define a set of pseudo time-series indices P = {p1, p2, ...pk} where each pi
is a T length vector where T > 0. We define pij as the jth element of pi and each
pij ∈ {1, ...,m}. We define the function F (pi) = [pi1, ..., piT ], creating a T by n
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matrix where each row of F (pi) = D(pij). Pseudo time-series can be constructed
from each pi using this operator. For example, if a pseudo time-series index vector
p1 = [3, 7, 2] then F (p1) is a matrix where the first row isD(3), the second row isD(7)
and the third row is D(2). The corresponding class vector of each pseudo time-series
generated by F (pi) is given by G(pi) = [C(pi1), ..., C(piT )].
To demonstrate this notation consider the following example:
Let the data matrix D be defined as:
D =

d11 d12 d13
d21 d22 d23
d31 d32 d33
d41 d42 d43
 , dij ∈ R
Let the corresponding class vector be C = [c1, c2, c3, c4]. If P = {p1, p2} where
p1 = [1, 3, 1] and p2 = [2, 3, 1] then:
F (p1) =

d11 d12 d13
d31 d32 d33
d11 d12 d13
 , G(p1) = [c1, c3, c1]
and
F (p2) =

d21 d22 d23
d31 d32 d33
d11 d12 d13
 , G(p2) = [c2, c3, c1]
To summarise, we defined a set of k pseudo time-series with their associated class
labels, sampled from the cross-sectional data D, indexed by the elements of pi.
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3.2 Floyd-Warshall Algorithm
We now briefly describe the Floyd-Warshall Algorithm [Flo62] which is used for the
generation of pseudo time-series. Graph-theoretical approaches such as this are com-
monly used to find the shortest paths between all nodes for a weighted graph G. A
weight matrix wij is an edge between node i and node j in graph G. An m×m matrix
representing the edge weights of an n-node graph, where W = (wij). This algorithm
is based upon a distance matrix D(k) which represents distance between data points
d(i) and d(j), where Dk = (dkij). A matrix d
k
ij is generated and represents the weight
of the shortest path from i to j using a set of nodes {1,2,...k} as intermediate nodes at
iteration k. If k is not a node on the path, the shortest path has length dk−1ij , otherwise,
the path is dk−1ik + d
k−1
kj . See Algorithm 1 for the full details.
Algorithm 1 The Pseudo code of Floyd-Warshall Algorithm.
Input: An m×m matrix W ;
1: D0 = W ;
2: for k = 1, ...,m do
3: Dk = dkij;
4: for i = 1, ...,m do
5: for j = 1, ...,m do
6: dkij = min(d
k−1
ij , d
k−1
ik + d
k−1
kj );
7: end for
8: end for
9: end for
Output: Dn
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We will use this algorithm within the pseudo time-series construction in order to
build trajectories between samples of cross-sectional data as detailed in the next sec-
tion. We use Euclidean distance between data points to build the matrix W .
3.3 The Temporal Bootstrap
The temporal bootstrap is a resampling approach for building pseudo time-series as
defined in Section 3.1. It involves resampling data from a cross-sectional study and
repeatedly building trajectories through the samples in order to build more robust time-
series models. Each trajectory begins at a randomly selected datum from a healthy
individual and ends at a random datum classified as diseased. An extension of the
temporal bootstrap is explored in this research, which allows us to identify intermediate
stages in a disease process and sub-categories of known diseases with subtly different
symptoms.
This method is compared to a strawman approach and its ability to inform us about
the dynamics of the disease is examined. In particular, the ability of the method to
explain the dynamics of disease progression, that results in trajectories through the
data space starting at healthy data regions and ending at cases of advanced disease,
is investigated. The hypothesis underlying the extended bootstrap approach is tested
on biomedical data from three diseases in order to identify automatically the disease
regions of interest at key junctions and the ‘extreme’ end of the trajectories. We use
HMMs in conjunction with the EM algorithm for the identification of disease regions.
The data is firstly standardised to a mean µ of zero and a standard deviation σ of
one as we found that this led to better HMM models. The elements of pi (as described
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in Section 3.1) are determined based upon a uniform random sampling procedure with
replacement. The ordering of the elements in pi is based upon randomly selecting a
start and an end in pi such that the associated classifications are cstart = 0 and cend = 1.
This means that the time-series will progress from a healthy state to a disease state.
The ordering is then determined by the shortest path, calculated based upon the Floyd
Warshall algorithm [Flo62] (Algorithm 1) applied to the Euclidean distance matrix,
Rij between samples in F (pi). See Algorithm 2 for the full details.
Algorithm 2 The Temporal Bootstrap for Learning Pseudo Time-Series Models from
Cross-Sectional data.
Input: Cross-section data D; class labels C, sample size T; number of pseudo
time-series k;
1: Standardise dataset D to µ = 0 and σ = 1;
2: for i=1 to k do
3: Uniformly randomly sample (with replacement) T row indices from D to create
di such that there is at least one healthy and one diseased class (in C) corre-
sponding to any of the indices in di;
4: Uniformly randomly select a row index from di, start, from where 1 ≤ start ≤
T and an endpoint, end, where 1 ≤ end ≤ T where C(di, start) represents a
healthy class and C(di, end) represents a diseased class;
5: Construct a T × T matrix, Wi, of Euclidean distances between each D(dia) and
D(dib) for all combinations of indices in di;
6: Order di to create d∗i based upon the shortest path between D(di, start) and
D(di, end) given the weighted graph Wi using the Floyd-Warshall algorithm
constrained so that every index in di is included in the path;
7: Add the ordered d∗i to the set of pseudo time-series P ;
8: end for
9: Use the set P of k pseudo time-series to train a time-series model
Output: Pseudo Time-Series Model
As an example we can explore how well multivariate time-series models can be
reverse-engineered from cross-sectional data by simulating the cross-sectional study
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process. Figure 3.1 shows the result of simulating a varying number of time-series
from an autoregressive hidden Markov model (ARHMM) with two disease states and
one healthy state. The data shown is a result of sampling a single point from each series
randomly (essentially generating a cross section of the population of time-series).
Figure 3.1: Scatter plot of the first two components using multidimensional scaling on
simulated data (generated from an Auto-regressive hidden Markov model (ARHMM)
with 3 states, one representing healthy control patients - red dots, and two representing
different disease symptoms - green and blue dots). Two of the original MTS are plotted
along with the full cross sectional data (one sampled form each MTS).
We can then use the temporal bootstrap to learn pseudo time-series prior to building
a pseudo temporal model. The error rate (Table 3.1) and classification accuracy (Table
3.2) resulting from the pseudo time-series models by using Temporal Bootstrap (TBS)
are shown, compared with the statistics generated from a model learnt from the original
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multivariate time-series (Full MTS). It should be noticed that the TBS results actually
appear to be better than the model inferred from the full MTS. This is because the
resampling process in the TBS procedure smooths the data and also shown the results
of the full MTS after smoothing, which are the most accurate (as would be expected -
it is highly unlikely that the pseudo time-series will generate more accurate models).
However, as the sample size increases and approaches 500, the statistics appear to
almost converge (results taken form [TGH10]).
We have been testing this approach on real cross-sectional datasets (VF, BC and
PD’s), where we can validate the outcome using longitudinal data, revealed similar
results. The next section illustrates the sample pseudo time-series generated from those
three cross-sectional datasets.
Length Full MTS TBS MTS smoothed
50 0.129± 0.039 0.251± 0.228 0.095± 0.055
100 0.126± 0.023 0.158± 0.121 0.086± 0.012
250 0.126± 0.013 0.079± 0.034 0.084± 0.014
500 0.125± 0.015 0.067± 0.023 0.084± 0.014
Table 3.1: Mean Forecast Sum Squared Error and 95% Confidence for Model Learnt
using the Temporal Bootstrap on Cross-Sectional Data (TBS), the Original Time-Series
with smoothing (MTS smoothed) and without (MTS).
Length Full MTS TBS MTS smoothed
50 0.907± 0.047 0.897± 0.092 0.903± 0.055
100 0.905± 0.045 0.912± 0.044 0.905± 0.048
250 0.905± 0.046 0.910± 0.046 0.905± 0.048
500 0.905± 0.046 0.912± 0.044 0.904± 0.049
Table 3.2: Mean Classification Forecast Accuracy and 95% Confidence for Model
Learnt using the Temporal Bootstrap on Cross-Sectional Data (TBS), the Original
Time-Series with smoothing (MTS smoothed) and without (MTS).
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3.4 Predictive Models and Their Mathematical De-
scription
Having built trajectories from cross-sectional data using pseudo time-series approach-
es, we then explored different techniques to model these sequences. As discussed in
Section 2.3.1, statistical approaches such as the Box Jenkins model [BJR13] are data
intensive and can be problematic when modelling uncertain and noisy data. Proba-
bilistic graphical models, however, have the natural ability to deal with this sort of data
and also allow for combining data with expert knowledge or, in case there are no data,
rely entirely on expert knowledge. This makes probabilistic graphical models such as
hidden Markov models (HMMs) and dynamic Bayesian networks (DBNs) particularly
attractive and popular in practice.
3.4.1 Mathematical Description of Hidden Markov Model (HMM)
A popular probabilistic model for modelling sequential and time-series data is known
as the Hidden Markov Model (HMM)[Rab89], which assumes a single discrete hidden
state,H and a continuous observed process,X . HMMs have widespread application in
a variety of tracking scenarios, from speech recognition to clinical analysis ([Rab89],
[WP02], [ZOM99], [Edd98], [LKBJ08], [SBR07]). Two characteristics of HMMs
provide [Rab89] strong support for the choice to use them in this research: firstly, the
models have a ‘complete’ mathematical architecture and refer to a wide range of appli-
cations; Secondly, they are a very accurate approach for some important applications
when applied properly. See Figure 3.2 shows the general architecture of HMMs, where
directed links determine conditional probability distributions. It involves one hidden
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variable that is conditioned on the hidden variable at the previous time point and n ob-
served variables that are conditioned upon the hidden variable at the same time point.
The transition equation is modelled using a discrete distribution of the state H at time
t, H t conditioned upon the state at t− 1. This is written as p(H t|H t−1) (and gives rise
to the link H t−1 → H t in Figure 3.2). The measurement equation is captured using
the distribution of each variable at time t conditioned upon the hidden state at time t,
written as p(X t|H t) (giving rise to the links, H t → X t1, H t → X t2, ..., H t → X tN ).
The forward algorithm allows the probability of the hidden state at time t, H t to be es-
timated from the previous and current values of measured variables, X1...t. To predict
p(H t|X1...t), H t represents the hidden state at time t and X t represents the variables
in the time series. This process is known as filtering and can be used to estimate future
probabilities of disease states from historical longitudinal data.
There are three basic problems associated with learning HMMs which are useful
in real-world applications [Rab89]:
• Problem 1: Given the observation sequence and a model, how to efficiently com-
pute the probability of the observation sequence, given the model?
• Problem 2: Given the observation sequence and the model, how to choose a
corresponding state sequence which is optimal in some meaningful sense?
• Problem 3: How to adjust the model parameters to maximize the probability of
the observation sequence, given the model?
Predictive models such as HMMs contain unknown parameters, known observed
data and latent variables. The forward or backward procedure of HMMs enable to be
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Figure 3.2: Architectures of Hidden Markov Models (top) and Dynamic Bayesian Ne-
towrks (bottom).
used because it is more efficient than direct evaluation. In order to find optimal or
the best state sequences in continuous nature, the sources are non-stationary vary over
time. The Baum-Welch algorithm can be used to solve the three problems where are
listed above in the learning process of HMMs. The Baum-Welch algorithm [Bag01]
is basically the application of expectation-maximization (EM) algorithm [B+98] to H-
MMs. EM is an iterative method, which can be used to find the maximum likelihood
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of parameters in statistical model with unobserved latent variables. Implementing the
EM algorithm for HMMs is straightforward and consists of two steps: first, the esti-
mate of the parameters for a HMM given a set of observed data (expectation step -
E step), is used to allow the evaluation of expectation of the log-likelihood; then the
maximum likelihood is estimated (maximization step - M step), in order to maximize
the expected log-likelihood found in the E step. The particular application of the EM
algorithm for this work can be described as ([Wik13],[Bor09]):
Expectation Step: Calculate the expected value of the log-likelihood function.
Q(θ | θt) = EZ|X,θt [logL (θ;X,Z)] (3.4.1)
Maximization Step: Maximize the quantity of the parameter.
θ(t+1) = argmax
θ
Q(θ | θt) (3.4.2)
where,
• X is a set of observed data associated with each data point.
• Z is a set of unknown latent variables, extract from a fixed number of values and
each observed data point has a latent variable.
• θ is a continuous vector of unknown parameters, which are associated with all
data points, and also with a particular value of a latent variable.
• Q(θ | θt) represents the conditional distribution of Z given X under the current
estimate of the parameters θ.
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3.4.2 Mathematical Description of Bayesian Networks (BNs)
Bayesian Networks [Bar12] are probabilistic networks that provide a way to represent
the independence assumptions made in a distribution. A Bayesian Networks defined
as follows [MP01b]:
P (X1, ..., Xt) =
N∏
i=1
P (Xi | Pa(Xi)) (3.4.3)
where Pa(Xi) is the parent set of a node Xi.
The three elements of DAG (the conditional probabilities, the structure and joint
probability distribution) can be used to estimate the probability or likelihood of each
variable or state. Mihajlovic [MP01b] points out three rationales why BNs are useful:
• From known causes to unknown effects (causal reasoning)(e.g we know the dis-
ease exist and the current state, and aim to explore and predict the end state of
the disease - longitudinal studies.), and
• From known effects to unknown causes (diagnostic reasoning) (e.g we known
the several end states of disease, but we aim to explore the causes of the disease
and the progression - cross-sectional studies.), or
• For any combination of these two.
If we want to know all of the conditional probabilities throughout the network we
need to adjust the parameters of the network, so that ‘Learning’ plays an importan-
t role to enable us to overcome the problems. Many different approaches have been
used to learn good BNs structures, such as the K2/K3 algorithms ([CH92], [Bou93]),
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the Branch and Bound technique [Suz93], and evolutionary methods ([LPY+96],
[WLL99]). K2/K3 can be described as greedy search which explores the effect of
adding each of the possible links to the current structure based on an empty structure
with no links and the one that finishes with the best score is selected. K2/K3 use this al-
gorithm with a log likelihood metric and a description length metric, respectively. The
Branch and Bound technique is used to perform an effective thoroughgoing search by
stopping any further exploration along a search route found on an edge which is delib-
erate on the scoring metric. When evolutionary methods are applied to static BNs the
application of various operators is compulsory to prevent the generation of recurrent
event within the network.
Learning BNs is the process of scoring candidate network structures. The log
likelihood ([CH92], [Gei92]) and the Description Length (DL) ([LB94], [Suz93]) are
two scoring metrics. The log likelihood is calculated by using expression 3.4.4, and
the higher score indicates the best structure that can be obtained to fit the dataset.
The Description Length metric is constructed from the summation of the description
length of a network structure (expression 3.4.5) and the description length of encoding
the dataset given that model (expression 3.4.6). In contrast to the log likelihood, the
lower this score is, the better the structure fits the dataset.
log
n∏
i=1
qi∏
j=1
(ri − 1)!
(Fij + ri − 1)!
ri∏
k=1
Fijk (3.4.4)
n∑
i=1
|pii| log(n) +
(
(ri − 1)
∏
j∈pii
rj
)
(3.4.5)
47
n∑
i=1
qi∑
j=1
ri∑
k=1
−Fijk × log
(
Fijk
Fij
)
(3.4.6)
where,
• n is the number of nodes.
• Fijk is the frequency of occurrences in the dataset that the node xi takes on the
value vik (where there are ri possible instantiations).
• the parent nodes take on the instantiation wij (where there are qi possible instan-
tiations) and the parent nodes pii take on the instantiation wij (where there are qi
possible instantiations).
• and Fij =
∑ri
k=1 Fijk.
3.4.3 Mathematical Description of Dynamic Bayesian Networks
(DBNs)
Dynamic Bayesian networks (DBNs) ([FMR98], [Gha98]) are an extension of the s-
tandard Bayes network as discussed in the Section 2.3.2.1, which are used to model
probability distributions of random variables. DBNs have similar hidden process as
hidden Markov models, but they are more general than hidden Markov models, which
assume a single discrete variable representing a hidden state and possible multiple ob-
servation variables. Each state at time t depends on its past given state at time t − 1.
For complex structure, it may also depends on more past states in the same time occur-
rence. A Dynamic Bayesian network is defined as follows[vGTL08]:
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P (X1...t) =
T∏
t=1
N∏
i=1
P (X it) | Pa(X it)) (3.4.7)
where,
• X it is the ith node representing the variable at time slice twith nodes correspond-
ing to a set of random hidden-state variables X(t),
• Pa(X it) are the parent of X it in the graph,
• P is the joint probability distribution (JPD) of variables in X(t).
DBNs are the probabilistic directed graphical models in which each node repre-
sents a variable at a particular time-slice. Each arc in the graph represents a probabilis-
tic relationship. The lack of arcs between nodes represents conditional independence
assumptions. The arcs connect parent nodes to child nodes and form a directed acyclic
graph (DAG), i.e. no directed cycles are admitted. Links can occur both in the same
time slice and between different time slices. Each node is associated with a conditional
probability distribution (CPD), which describes the probability of each possible value
of the variables given their parents. Once the structure of the network and the CPDs
are obtained, it is possible to infer the value of any node. In fact, all the CPDs of the
DBN provide an efficient factorization of the joint probability of the variables in the
model. A simple example is shown in Fig 3.2. To build a DBN, the structure of the
network and the three set of parameters (state transition, observation probability distri-
bution function and initial state distribution) (i.e. the CPDs) of all the variables must
be obtained. Typically, the CPDs are learned from data by maximizing the posterior
probability of the parameters given the data [HGC95]. When the structure is fixed and
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the prior distribution of the parameters is uniform, this corresponds to maximizing the
likelihood function.
In the learning process of DBNs, a similar approach to standard BNs can be adopt-
ed (such as a search and score with an appropriate metric e.g. log likelihood). For
example, the REVEAL algorithm [LFS+98] is a modified equivalent of the K2 algo-
rithm. In [TLOS01], a number of existing BN learning algorithms were adapted for
DBNs. However, in many time-series, there are changes in the underlying distributions
and standard DBNs cannot take this into account as they are time-invariant. More re-
cently, non-stationary DBNs have been explored where both a model parametrisation
and a segmentation process are performed to identify these changes in structure. How-
ever, the search space is usually limited by constraining one or more degrees of free-
dom, i.e. the segmentation points of the time series, the parameters of the variables,
the dependencies between the variables and the number of segments for the model.
Among the most recent and complete work, Talin and Hengartner [TH05] used a M-
CMC approach to estimate the variance structure of the data, but the search space was
limited to a fixed number of segments and for learning undirected edges only. Xuan
and Murphy [XM07] proposed an approach to model changing dependency structures
from multivariate time series, but also in this case the search was limited to undirect-
ed edges. Robinson and Hartemink [RH10] formalized the concept and proposed a
solution that tackles all the degrees of freedom described except for the parameters.
Grzegorczyk and Husmeier [GH09] instead retained the stationarity of the structure
in favour of the parameters flexibility, arguing that structure changes lead almost cer-
tainly to over-flexibility of the model with short time-series. While the first approach
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may only capture parameter changes that are strong enough to give rise to a struc-
tural change, the latter may not model correctly underlying conditional dependencies
over the stages. The ability to assess both weak and strong changes in variable distri-
butions and explicitly model the evolution of their relationships would be extremely
useful from an informative point of view, especially in unknown processes such as
glaucoma. In [CGHCT12] a form of DBN that clusters sections of time series whilst
simultaneously learning DBN structure and parameters was used to model glaucoma
patients. The Bayesian Information Criterion (BIC) [Sch78] was used in conjunction
with Simulated Annealing (SA)[KJV83] for learning both the BNs and the clusters.
BIC incorporates a penalizing factor that is proportional to the number of parameters
in the model and the number of cases in the data, and helps to prevent overfitting.
3.4.4 A proposed Algorithm for Identifying Key Stages in a Dis-
ease Process
An algorithm is proposed in this PhD study for identifying key stages in a disease
process. A key novelty of this work is the use of the temporal bootstrap in conjunc-
tion with Algorithm 3 described, below, to generate and explore the transitions of the
different states within the trajectories that are discovered from the selected data. As
shown in the algorithm, essentially, it starts by searching for hidden states h = 3 (one
more than the original ‘healthy’ and ‘disease’), whilst learning a HMM. The HMM is
chosen here in conjunction with the Expectation Maximisation algorithm for its ability
to learn hidden underlying states in a temporal process.
The Expectation Maximisation (EM) algorithm [B+98] can be used to cluster a
sequence of data into different sections. It consists of two steps:
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• The E step becomes the sum of expectations of sufficient statistics
• the M step involves maximizing a linear function.
In order to cluster the data into increasingly fine-grain regions using the EM algorithm,
the EM model fitting process is repeated for increasing values of h and the transition
matrix of the HMM is explored manually each time for interesting features. Thus, this
iterative interactive approach is a good way to ensure interesting features are identified.
In addition, it is can be used to minimize the cost function of the network. The process
is detailed in Algorithm 3 below:
Algorithm 3 An iterative algorithm for identifying key stages in a disease process.
Input: A set of pseudo time-series, P generated from cross section data D and
associated labels C;
1: Remove the class labels C from P ;
2: Set h = max(C) (the number of classes) + 1;
3: repeat
4: Train a HMM on the P with h hidden states using the EM algorithm [B+98];
5: h = h+ 1;
6: until
7: Transition table in the parameterised HMM captures disease features of interest
(e.g. it features more than one clear end state);
Output: HMM with new intermediate or end states
By applying this approach we aim to identify different key stages in a disease pro-
cess [LT10]. Furthermore, the ordering of the discovered sequences (i.e. the pseudo
time-series) should lead to more informative clusters and transitions than simply clus-
tering the unordered cross-sectional data using, for example, standard clustering such
as K-means [HW79].
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3.5 Summary
In this chapter, different approaches to modelling trajectories through clinical data have
been examined. Firstly, two methods to infer time-series from data are discussed. This
includes hidden Markov models and dynamic Bayesian networks which are especially
good at dealing with uncertainty and noise. Secondly, some new techniques for build-
ing trajectories through cross-sectional data are explored with a focus on sequence re-
construction. It is clear that many of the longstanding approaches to modelling disease
progression are proving inadequate to deal with issues of uncertainty in the dynam-
ic and measurement processes and the ability to integrate cross-sectional studies with
longitudinal studies. The approaches and techniques discussed in this chapter will
be further discussed in the next two chapters. Examples of real cross-sectional data
and simulated data that are designed to mimic the cross-sectional study data collection
process will be described with analyses of pros and cons in the next chapter.
Chapter 4
Identifying Key Stages in a Disease
Process from Cross-Sectional Data:
Experiments and Results
This chapter presents the results from the experiments of using methods and algorithms
described in chapter 3, utilising both simulated data and the three clinical datasets are
discussed in this chapter. The simulated results consist of time-series generated by an
autoregressive HMM. The sample trajectories are constructed using the temporal boot-
strap on each dataset, plotting the first two components, following multi-dimensional
scaling. The comparison of the trajectories within a medical context is illustrated.
Following that, the State-End diagrams used to represent the transition probabilities
between the different states are discovered. The mean values of the clinical data are
presented for both healthy and diseased patients for comparative purposes. Addition-
ally, the expected data values for each state associated with the state-end diagrams are
also discussed, based upon the HMM learnt from the unlabelled pseudo time-series.
All the results in this chapter have been published on number 2 [LT10] and 3 [YSA13]
publications.
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4.1 Simulated Data and Experiment Setups
In order to assess the performance of the different approaches explored in this section,
a number of simulated datasets are used which are now described. In power analysis,
simulation is a simplified imitation of the operation of a real-world process through
time, that follow a particular distribution and calculating the test statistic from each
sample. So that the significance level and power of the procedure may be investigated.
In this research, a number of simulated time-series are generated from an autoregres-
sive HMM (ARHMM) ([HDA01], [KIM03], [KT02]) with two variables for ease of
visualisation (essentially it is a bivariate Gaussian). 200 time-series datasets are gener-
ated with four or five discrete states in order to determine the trajectory of each time-
series. The number of samples was chosen to reflect the typical sample sizes from the
available clinical data. An autoregressive hidden Markov model (ARHMM) was used
as to capture the relatively smooth transition from healthy to disease states through
autoregressive dependencies. This smooth transition is typical in many medical data
and particularly in progressive diseases such as glaucoma. For some diseases, this may
not hold if their symptoms fluctuate, appearing and disappearing over the course of the
disease.
The states and the transitions between ‘healthy’ and ‘diseases’ are based upon the
discussion on multiple end points in Chapter 2 (Albert [Alb99]). The states in the first
simulated dataset represent a starting healthy region and one diseased region with two
intermediate states, whilst the second dataset involves one starting state, two end states
and two intermediate states. The observed variables are Gaussian and conditioned
upon the hidden state and the same variable at the previous time point. The length of
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each multivariate time-series is set to 30, as this reflects common longitudinal studies in
the biological and medical literature. The hidden variable always starts in the healthy
state and has a probability distribution that determines the probability of change to
the intermediate and end states. One point from each time-series is then sampled to
form a cross-sectional dataset. This process is similar to that used in [CK02] and an
example of the cross-sectional data is plotted in Figure 4.1 including some time-series
examples.
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Figure 4.1: Two simulated datasets generated using autoregressive HMMs with two
variables to model disease processes. The plots show a single sampled point from each
time-series (dots) along with some of the original time-series (lines). One dataset has
1 healthy state, 1 disease state and 2 intermediate states (top); the second dataset has 1
healthy state, 2 disease states and 2 intermediate states (bottom).
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4.2 Simulated Results
To demonstrate the power of the proposed methods, the two simulated time-series
datasets are generated (see Figure 4.1) using an autoregressive HMM with two vari-
ables to model a disease process with both healthy state and different disease states.
The plots show a single sampled point from each time-series (dots) along with some of
the original time-series (lines). One of the datasets has 1 healthy state, 1 disease state
and 2 intermediate states; the other one has 1 healthy state, 2 disease states and 2 in-
termediate states. The underlying reason for that choice is to capture complex advance
disease scenarios as highlighted in the literature (specifically [Alb99]). We sample one
point from each time-series generated in this data to represent cross-sectional data and
use it to generate Multivariate Pseudo Time-series (MPTS).
The resulting transition matrices generated from applying Algorithm 2 (see Section
3.3 in Chapter 3) to the two simulated datasets are shown in Tables 4.2 and 4.4, and
the visualisation of transition matrix are shown in Figure 4.3 and 4.5. By comparing
with the original matrices in Tables 4.1 and 4.3, it can be seen that although the precise
probabilities are not discovered, the general characteristics of many of the states are
actually found (see the visualisation of original matrix from Figure 4.2 and 4.4). The
stable end states (state 4 in Table 4.2, and states 4 and 5 in Table 4.4) with spurious
dynamics are the examples for this. Testing the discovered model using the original
(unseen) full time-series data gives a mean accuracy of 95% (see Section 3.3 in Chapter
3), indicating that a very reliable time-series model can indeed be learnt from cross-
sectional data if the sample is sufficiently large enough. For example, states marked
with an asterisk correspond to zero probabilities in the original model. Although these
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spurious correlations are small, it is found though that as the sample size of the original
data is reduced (to 50 or less), they become more of an issue. They are likely to
have occurred because the learnt HMM overfitted spurious relationships in the MPTS
through implicit correlations. In summary, the main characteristics of the transitions
are preserved when the sample size is appropriately high. A small number of spurious
correlations between impossible transitions were generally observed but these were
always very low values. This gives a confidence in exploring the real-world clinical
datasets with similar sample sizes.
Ht−1 \ ht 1 2 3 4
1 0.800 0.100 0.100 0.000
2 0.050 0.900 0.000 0.050
3 0.050 0.000 0.900 0.050
4 0.000 0.000 0.000 1.000
Table 4.1: Transition matrix for hand-coded simulated data with 4 states.
Ht−1 \ ht 1 2 3 4
1 0.833 0.061 0.091 0.015∗
2 0.277 0.566 0.000 0.157
3 0.213 0.000 0.729 0.058
4 0.000 0.025∗ 0.077∗ 0.898
Table 4.2: Transition matrix learnt from PTS discovered from cross-sectional sample
of simulated time-series with 4 states.
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Figure 4.2: The visualisation of transition matrix for hand-coded simulated data with 4 states.
Figure 4.3: The visualisation of transition matrix learnt from PTS discovered from cross-sectional sample of simulated
time-series with 4 states.
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Ht−1 \ ht 1 2 3 4 5
1 0.800 0.050 0.050 0.050 0.050
2 0.050 0.900 0.000 0.050 0.000
3 0.050 0.000 0.900 0.000 0.050
4 0.000 0.000 0.000 1.000 0.000
5 0.000 0.000 0.000 0.000 1.000
Table 4.3: Transition matrix for hand-coded simulated data with 5 states.
Ht−1 \ ht 1 2 3 4 5
1 0.892 0.028 0.046 0.015 0.020
2 0.076 0.686 0.000 0.238 0.000
3 0.119 0.000 0.577 0.000 0.304
4 0.002∗ 0.016∗ 0.000 0.951 0.031∗
5 0.086 0.000 0.070∗ 0.004∗ 0.841
Table 4.4: Transition matrix learnt from PTS discovered from cross-sectional sample of simulated time-series with 5 states.
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Figure 4.4: The visualisation of transition matrix for hand-coded simulated data with 5 states.
Figure 4.5: The visualisation of transition matrix learnt from PTS discovered from cross-sectional sample of simulated
time-series with 5 states.
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4.3 Real-World Cross-sectional Datasets
The three datasets used in this study are named after the disease conditions.The first
dataset - Visual Field (VF) and Heidelberg Retina Tomography (HRT) data is from
glaucoma sufferers. Glaucoma is an eye disease, characterised by progressive loss
of vision and is the second major cause of blindness worldwide. The dataset is built
based upon two kinds of medical tests for glaucoma. The second dataset - Breast Can-
cer (BC) data is from breast cancer sufferers. Breast Cancer is a kind of cancer from
breast tissue that supply the ducts with milk. The majority of disease cases occur in
women, the incidence of breast cancer is rising among women in many European coun-
tries, profoundly affecting up to 1 in 16 women [Org10]. The dataset is set upbased
upon tumour examinations for breast cancer. The last dataset - Parkinson’s disease
(PD) is from a Parkinson’s disease sufferers. Parkinson’s disease is idiopathic disease,
characterised by a degenerative of the central nervous system and having no known
cause, most of cases occurring in the old people. Because of the ageing of the world,
parkinson’s disease has become an increasing public health issue due to the ageing of
the world’s population [Org98]. The dataset is built based on speech pattern data for
Parkinson’s disease. Although, these diseases are very different, the datasets share a
similarity in terms of how data has been collected, as all of them come from cross-
sectional studies over a relatively large population. These sampled cross-sectional data
are used to generate the Pseudo Time-Series. The three clinical datasets are described
individually in the next sections. Table 4.5 gives a summary of the datasets:
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Dataset Number of Variables Number of Cases %age of Healthy Controls
Visual Field 12 163 51.9
Breast Cancer 10 565 62.7
Parkinson Disease 22 195 24.6
Table 4.5: Summary table of the 3 datasets.
4.3.1 Visual Field Test and Heidelberg Retina Tomography Data
The Visual Field (VF) test assesses the sensitivity of the retina to light. It is typically
measured by automated perimetry, a technique in which the subject views a dim back-
ground as brighter spots of light are shone onto the background at various locations
in a regular grid pattern. The brightness at which the subject sees the spots of light
is related to the retinal sensitivity. There are many diseases and conditions that affect
the VF, the most common being neurological disease and glaucoma. For this study,
the data are aggregated into average values based upon their association with one of 6
nerve fibre bundles based upon the mappings in [KCO02]. The other type of data that
we explore are obtained by Heidelberg Retinal Tomography (HRT) [LCS+06] which
involves generating images of the retina in order to calculate certain measurements
associated with the three dimensional shape of the optic nerve head. These include
neuro-retinal rim area measurements, which are used for the experiments in this study.
The measurements are calculated for 6 different segments of the retina: nasal (n), nasal
inferior (ni) and superior (s), temporal (t), temporal inferior (ti) and temporal superior
(ts). For the experiments in this study, we combine the VF and HRT datasets to see
if trajectories that are identified capture the interaction between the two data types as
glaucoma progresses. The VF and HRT data are taken from a study of approximately
163 people [Log05] and each patient is classified into healthy or glaucomatous based
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upon the VF data, using a pre-defined algorithm (AGIS). This may result in a bias to-
wards the VF data for the building of the pseudo time-series, however as the relabelling
algorithm involves learning the states from scratch we do not envisage it biasing our
final disease stages.
4.3.2 Breast Cancer Data
The 565 Breast Cancer data (BC) are classified into 212 malignant and 357 benign
cases. Ten real-valued features are computed for each cell nucleus: radius, texture,
perimeter, area, smoothness, compactness, concavity, concave points, symmetry, and
fractal dimension. The original dataset is described in more detail in Wolberg and
Mangasarian and is available from the UCI machine-learning repository [A.K96].
4.3.3 Parkinson’s Disease Data
Parkinson’s disease (PD) affects movement and motor-related symptoms including
speech. Vocal impairment can be the earliest indicator for the onset of PD. There-
fore, a number of voice measurements have drawn significant attention for detecting
and tracking the progression of symptoms of PD [Mit97]:
• The average vocal fundamental frequency (MDVP:Fo(Hz))
• The maximum vocal fundamental frequency (MDVP:Fhi(Hz))
• The minimum vocal fundamental frequency (MDVP:Flo(Hz))
• Several measures of variation in fundamental frequency (MDVP: Jitter(%), MD-
VP:Jitter(Abs), MDVP:RAP, MDVP:PPQ, Jitter:DDP)
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• Several measures of variation in amplitude (MDVP:Shimmer, MD-
VP:Shimmer(dB), Shimmer:APQ3, Shimmer:APQ5, MDVP:APQ, Shim-
mer:DDA)
• Two measures of ratio of noise to tonal components in the voice status (NHR,
HNR)
• Two nonlinear dynamical complexity measures (RPDE,D2)
• The signal fractal scaling exponent (DFA)
• Three nonlinear measures of fundamental frequency variation (spread1, spread2,
PPE)
The PD dataset is composed of 195 biomedical voice measurements, 147 of which
are from Parkinsons disease patients and 48 from controls. The original dataset was ob-
tained by McSharry and Roberts and is available on the UCI machine-learning reposi-
tory [MSP05].
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4.4 Biomedical Experiments and Results
In this research, the disease region identification is compared with standard clustering
techniques on real-world medical cross-sectional data. For the real world data, the true
underlying state transitions are unknown. However, the discovered transitions can be
explored in the medical context. The biomedical results provide some sample trajecto-
ries when using the temporal bootstrap on each dataset. Points are identified as healthy
and diseased using red/dark grey and blue/light grey respectively. These figures are
generated using multidimensional scaling (calculated with Euclidean distances). This
enables us to visualise many more variables in two dimensions. The ‘state diagrams’
(it is not a graphical model, it displays the non-zero entries of the transition matrix) are
given to represent the transition probabilities (p) between the different states discov-
ered. Associated with these diagrams, the expected values and clustering values for
the data for each state are produced, based upon the HMM learnt from the unlabelled
pseudo time-series. The mean values for the data for healthy patients and diseased
patients are shown for comparison. Note that Algorithm 2 given in Chapter 3 involves
increasing values for the hidden state h. Results provided here are only for the models
with the number of states that are the best compromise between finding new interesting
end and intermediate states, but not with trivial states that are simply side-effects of the
data. For the glaucoma data, 4 states were found which best met this balance; similarly
for the breast cancer, 5 states were gained; and for the Parkinson’s data with 3 states.
A larger value for h led to the splitting of interpretable states into ones with less clear
significance.
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4.4.1 Glaucoma
4.4.1.1 The Trajectories - Glaucoma
Figure 4.6: Typical trajectories learnt from the combined VF and HRT data plotted
using multidimensional scaling with Euclidean distance. Normal VFs are marked in
red and glaucomatous in blue.
Figure 4.6 shows sample trajectories that are discovered when building the pseudo
time-series from healthy to disease regions. It also highlights that there could be two
distinct regions of diseased state (in the top-right and bottom-right of the plot, marked
with two dashed ellipses). Although this is may not be shown the states properly at
this stage, the analysis below will confirm it through the relabelling scheme which is
used to identify the sequence transitions and their medical context.
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4.4.1.2 End-State Analysis - Glaucoma
The glaucoma state transition diagram generated from the transition matrix of the
learnt HMM is displayed in Figure 4.7. The figure shows transitions with a p > 0.15
as solid lines and p > 0.05 as dashed. The full transition matrix is given in Table 4.6
where ht represents the hidden state h at time t.
Figure 4.7: State Transitions for Glaucoma data. State 4 coincides with the starting
healthy state, 1 and 2 appear to represent relatively stable end states and 3 appears a
transitory state (a p > 0.15 is shown as a solid line and p > 0.05 as dashed).
Ht−1 \ ht 1 2 3 4
1 0.975 0.025 0.000 0.000
2 0.051 0.746 0.090 0.113
3 0.275 0.000 0.682 0.042
4 0.000 0.070 0.099 0.831
Table 4.6: Transition matrix for discovered VF states.
The table and the diagram show that there appear to be three relatively stable states:
1, 2 and 4. State 4 coincides with the starting healthy state, 1 and 2 appear to represent
relatively stable end states and 3 a transitory state. These states are further explored by
calculating the expected values of the variables associated with each state (see Figure
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4.9). The clustering values of the variables discovered using k-Means clustering (see
Figure 4.10) and compared with the mean values for normal and glaucomatous data
in Figure 4.8. All values were standardised to have a mean = 0 and sd = 1, to
void one of large data dominating the model. Expected state 4 in Figure 4.9 shows a
normal rim width and VF sensitivity (similar values to the control in Figure 4.8 with
high NFB sensitivity and low rim-associated variables), whereas state 1 shows marked
diffuse rim narrowing (high values for the rim-associated variables), and moderate loss
of retinal sensitivity (low values for the NFB sensitivities) similar to the glaucomatous
in Figure 4.7.
This is what would be expected, based on known anatomical relationships. State
3 (an apparently transitory state) displays narrowing of the rim but little reduction of
retinal sensitivity, whilst state 2 (a relatively stable state) shows some narrowing of
rim, but no loss of retinal sensitivity. This characteristic progression in the field but
not in the optic disc (as displayed in the HRT rim data) and vice versa is known to
occur and it is interesting that these have been identified by the algorithm as precursors
to full disease progression. More informative clusters are discovered using our ap-
proach. Furthermore the pseudo-temporal models will further assist in understanding
the progression of Glaucoma.
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Figure 4.8: The mean data for the VF (top) and HRT (bottom) data as pre-classified
using clinical analysis. NFB represent the sensitivity of a specifier Never Fibre Bundle
with the VF, and Diff rim represents the rime narrowing regions.
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Figure 4.9: The expected data for VF and HRT discovered using Algorithm 2.
Figure 4.10: The mean cluster profiles for VF and HRT discovered using k-means
clustering.
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4.4.2 Breast Cancer
4.4.2.1 The Trajectories - Breast Cancer
Figure 4.11: Typical trajectories learnt from the BC data. Benign are marked in red
and Malignant in blue.
Figure 4.11 shows sample trajectories for the BC data. There is a clear cluster of
benign tumours in red and those classified as malignant in blue. We use the relabelling
scheme to see if we can identify the state transitions from healthy/benign to malignant.
4.4.2.2 End-State analysis - Breast Cancer
The BC state transition diagram generated from the transition matrix of the learnt H-
MM is illustrated in Figure 4.12 (the figure shows transitions with a p > 0.15 as solid
lines and p > 0.05 as dashed). The full transition matrix is given in Table 4.7. This
table and diagram show that there appear to be four relatively stable states: 2, 3, 4 and
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5. State 3 appears to coincide with the starting benign state, whilst state 2 represents a
relatively stable malignant state. States 1, 4 and 5 appear to be transitory states, with
state 5 being a key stage in the progression to advanced malignant tumour. The states
are further explored by comparing the mean data for the pre-classified benign and ma-
lignant states (Figure 4.13) with the expected values of the variables, associated with
each discovered state as shown in Figure 4.14. The clustering values of the variables
discovered for the BC data using k-means clustering, as shown in Figure 4.15.
Figure 4.12: State transitions for the BC data. State 3 appears to coincide with the
starting benign state, whilst 2 appears to represent a relatively stable malignant state,
and 1, 4 and 5 to be transitory states, with state 5 being a key stage in the progression
to advanced malignant tumour (a p > 0.15 is shown as a solid line and p > 0.05 as
dashed).
Ht−1 \ ht 1 2 3 4 5
1 0.6963 0.0000 0.0403 0.0541 0.2093
2 0.0000 1.0000 0.0000 0.0000 0.0000
3 0.0959 0.0000 0.8929 0.0112 0.0000
4 0.0417 0.0377 0.1021 0.7764 0.0422
5 0.0000 0.1464 0.0000 0.0629 0.7907
Table 4.7: Transition matrix for discovered BC states.
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State 3 does indeed seem to represent people with benign tumours (with generally
low values for all metrics as seen in the benign cases in Figure 4.13), whereas state 2
represents cases of malignant BC (with generally high values as seen in the malignant
cases in Figure 4.13). Interestingly, state 5, which looks like an intermediate stage in a
trajectory will ultimately be in a state characterized as a malignant tumour. This shows
characteristics of a malignant tumour but only in some variables such as high values
for radius, perimeter and concave points. Other variables such as fractal complexity
appear normal.
Figure 4.13: The mean data values for the pre-classified benign and malignant cases.
Here, the expected values from our approach are not really more informative than
k-Means. However, our approach still offers the advantage of building transition mod-
els which help to understand the progression of the disease.
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Figure 4.14: The expected values of data for each state discovered from the relabelling
scheme on the BC data.
Figure 4.15: The mean cluster profiles for the BC data using k-Means clustering.
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4.4.3 Parkinson’s Disease
4.4.3.1 The Trajectories - Parkinson’s Disease
Figure 4.16: Typical trajectories learnt from the PD data. Healthy are marked in red
and Parkinsonism in blue.
Figure 4.16 shows a curved trajectory from healthy to Parkinsonism. Note that the
small cluster of healthy patients that appear to sit halfway through this trajectory after
many other patients have been classified as sufferers (marked with a dashed circle).
This is due to demonstrating a subset of symptoms and we explore this hypothesis by
using the relabelling scheme.
4.4.3.2 End-State analysis - Parkinson’s Disease
The PD state transition diagram generated from the transition matrix of the learnt HM-
M is shown in Figure 4.17 (The figure shows transitions with a p > 0.15 as solid lines
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and p > 0.05 as dashed).The full transition matrix is given in Table 4.8. This table
and diagram show that there appear to be two relatively stable states: 1 and 2. State 1
coincides with the starting healthy state and 2 appears to represent a stable end state
with 3 being a transitory state.
Figure 4.17: State transitions for the PD data. State 1 coincides with the starting
healthy state, state 2 appears to represent a stable end state, with 3 representing a
transitory state (a p > 0.15 is shown as a solid line and p > 0.05 as dashed).
Ht−1 \ ht 1 2 3
1 0.8860 0.0000 0.1140
2 0.0000 1.0000 0.0000
3 0.0771 0.0482 0.8748
Table 4.8: Transition matrix for discovered VF states.
The expected values of the variables associated with each state are shown in Fig-
ure 4.19, the clustering values using k-Means is shown in Figure 4.20 and the mean
values for the pre-classified Parkinsonism patients and controls are shown in Figure
4.18. State 1 in Figure 4.19 shows people with a healthy profile very similar to the
control profile in Figure 4.17. State 2 appears to resemble people with PD, especially
in the measurements of HNR (higher) and the three MDVP-related metrics (higher).
HNR represents Harmonics to Noise Ratio and is one of the most popular approaches
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to measuring voice function [PT07]. The three MDVP metrics capture the average,
maximum and minimum vocal fundamental frequency. In addition, DFA is one of the
parameters currently used to distinguish healthy people and people from PD sufferers,
since the scaling exponent of DFA is larger in PD than healthy people. It is positive
to see that the scale of this for state 2 is larger than the state 1 and 3. PEE is a new
measure of PD dysphonia, F0 is the natural pitch of healthy voices. State 2 seems to
be characterised by a much larger vibrato and micro tremor than State 1. Jitter is an-
other feature of PD and control measure values should be close to 0, as we see in the
State 1. State3 appears to be a transition state somewhere between the control and PD
stages, where certain key features seem to show characteristics of PD (such as RPDE
and DFA), whilst others resemble those of the controls. This state could account for
the cluster of apparently healthy individuals that look as if they are part way along
the trajectory in Figure 4.16. The expected results using our approach have more in-
formative clusters than static clustering of the original cross-sectional data, due to the
explicit modeling of the dynamics of the disease.
Figure 4.18: Mean PD data for pre-classified control and Parkinsons Disease.
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Figure 4.19: The expected data for each discovered state in the Parkinsonism Data.
Figure 4.20: Mean cluster profiles using k-Means.
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4.5 Summary
The results of the experiments utilising the approaches and techniques are discussed in
this chapter. For the real world clinical data, the true underlying state transitions along
a disease process are unknown. However, the discovered transitions can be explored
in the medical context. This chapter has empirically demonstrated the advantages of
the relabelling algorithm when applied to pseudo-time-series. The details are given
to show how key intermediate stages of disease can be identified and evaluated using
simulated data with complex multiple disease stages endpoints, as well as real clinical
data from three very different diseases.
The next chapter will address how to overcome some of the current weaknesses of
the pseudo time-series approach, namely the lack of genuine temporal information as
the trajectories are only built as sequences through the data without any time stamps. It
will explore how pseudo time-series can be calibrated using a small number of longitu-
dinal datasets in order to inject real time stamps into the models of disease progression.
Chapter 5
Calibrating Pseudo Time-Series
In chapter 3, a resampling approach known as the Pseudo Temporal Bootstrap (TBS)
[TGH10] was introduced. It aims to build multiple trajectories through cross sectional
data, in order to approximate genuine longitudinal data. These Pseudo Time-Series
(PTS) can then be used to build approximate temporal models for prediction. This
approach has been extended to cluster important stages in disease progression using
hidden Markov models and the EM algorithm [B+98] as discussed in Section 3.4.1.
However, the use of cross-sectional data to build these models will always be limited
by the fact that no genuine time stamps have been used to infer the models. This chap-
ter investigates the effect of incorporating genuine longitudinal data into the pseudo
temporal models in order to calibrate them. This part of the work explores how to best
balance combining the cross-sectional data with longitudinal data in order to minimise
the need for too many expensive longitudinal data samples whilst being able to learn
genuine temporal models.
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5.1 Integrating data
In this chapter, we discuss the integration of cross-sectional and longitudinal data. The
process of data integration normally involves combining data from different sources
and providing users with a consolidated data view. Many data integration techniques
address representation heterogeneity where similar data is stored in many different
forms, as commonly seen in bioinformatics data [AMMM07]. Data Warehousing
[Inm96] is key to many data integration projects (though still rare in biology and
medicine) as it involves restructuring multiple databases in order to allow rapid access
for analysis and data-mining through multidimensional modelling [CNF+07]. Meta
Analysis is also popular for data integration, particularly in ecological research where
data can be expensive to obtain [CGGW05]. It works by supplying a statistical
framework for identifying significant results over a number of independent published
studies, and calculating the significance of all of the studies when they are brought
together. It can be prone to publication bias where positive results are more likely
to be published and therefore skewing the statistics [JM02]. Here we are combining
data that contains the same essential variables (the clinical tests) the difference being
that some are generated over time from the same patient and others are only recorded
once per patient. Both types of data offer essential information, for example, disease
variation in the general population are normally from cross-sectional studies while
genuine temporal information of the disease from longitudinal data.
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5.2 Experiments and Results
For this study, we explore the effect of adding relatively small numbers of time series
to pseudo time-series generated from cross-sectional data, to see if the resulting mod-
els can be improved. Essentially it is to see if the limitations of pseudo time-series can
be overcome (due to the lack of time-element in the trajectories which are in reality se-
quences of data) by calibrating them with real time-series. We explore this calibration
on both simulated and real VF data.
5.2.1 Calibrating PTS on Simulated Data
For the simulated data, we generate time-series of length 30 from an autoregressive
hidden Markov model (ARHMM (original) in Figure 5.1) to mimic typical biomedical
longitudinal data (MTS). We then randomly sample a single point from these series to
mimic the cross-sectional sampling of a population (CS DATA) but reserve 50 for the
calibration.
Figure 5.1: The scheme of the experiments: non calibrated.
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Figure 5.2: The scheme of the experiments: calibrated.
The experiment starts with 500 cross-sectional samples, as this was found to be a
suitably large size to generate good pseudo time-series and models in [TGH10], and
increment by 100 up to 1500 (the size of some increasingly large biomedical studies
such as [GHLB+12]). The Kulbaeck Leibler (KL) distance [Kul87] is used to explore
how close a model learnt from the cross-sectional data using the temporal bootstrap is
to the original generating model. Figure 5.1 illustrates the general scheme.
A number of the reserved original time-series (Reserved MTS) generated by the
same ARHMM were then added to the pseudo time-series, and calibrated models are
learnt from this (Callibrated ARHMM in Figure 5.2). We explore how close these new
calibrated models are to the original model. Increments of 10 time-series were used as
these seem to differentiate between the KL distances significantly. We also include how
good the model is when learnt solely from the time-series used to calibrate the models
to check that it is not simply using these small longitudinal samples to parameterise
85
(see Figure 5.2)
A similar experiment was performed using real VF longitudinal of 91 patient time-
series. The data taken from a study of patients with Ocular Hypertension (often a
precursor to Glaucoma). Each patient undergoes VF examination on a 4 monthly basis,
hence the obtained time-series can be used to explore progression of the disease. The
full study is documented in [KGHR+03] and 91 patients were selected in this study
based upon a minimum number of visits. One VF test is sampled from each of these
selected patient’s time-series to generate a cross-sectional sample and generate PTS
data for learning models from. We then compare these models, as well as those learnt
from a combination of PTS and real time-series to see how close the resulting models
are to the one that is generated from the original longitudinal study. Figure 5.3 shows
the results for all experiments, including learning PTS from cross-sectional samples of
varying sizes and either not calibrating, calibrating with 10 time-series, or calibrating
with 20 time-series.
The first obvious characteristic of these graphs is that calibrating does indeed im-
prove the quality of the models with the KL distances that are closer to the original
generating ARHMM. This is not surprising seeing that there is no genuine “time”
in the PTS generated from the cross-sectional data. What is surprising, is that only
a relatively small number of time-series are needed to improve these models, espe-
cially when there are lots of samples used from the cross-sectional data. This well
supports the results from previous studies (Chapter 4) that the PTS does find good-but-
not-perfect models (limited by the lack of real time-series) and that a small number
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Figure 5.3: KL distance for varying cross-sectional study sample sizes with increasing
number of longitudinal data for calibration.
of genuine time-series can calibrate these models. These findings provides good sup-
porting evidence that expensive longitudinal studies can be relatively small in size if
combined with larger cross-sectional studies to capture the general trajectories and the
variability of disease progression within a population.
Figure 5.4 shows the confidence intervals of the KL distances generated from the
study. From the one with no calibration and with calibration from 10 time-series, it can
be seen that there is a steady decrease in KL distance as cross-sectional sample size
increases where more and more reliable PTS are constructed. When the sample size
is 1500, the KL distance mean becomes 1.70 +- 0.16. Note that when 10 time-series
alone are used to learn the model, a mean KL distance of 2.08 +- 0.26 is obtained. This
shows that the PTS generated from the cross-sectional data improves on models learnt
from the time-series only by incorporating the variability within a larger population
captured in the cross-sectional data. With calibration from 20 time-series, we see a
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similar story, where increasing the cross-sectional sample size, builds better PTS and
results in models that are closer to the original. For 1500 in the cross-sectional sample
we see a KL distance of 1.48 +- 0.12. Note that when 20 time-series alone are used to
learn the model we get a mean KL distance of 1.78 +- 0.15. Again, it proves that the
PTS improves on time-series alone, but that the integration of both seems to generate
the models that best reflect the underlying model.
We also explored the statistical significance of the differences between these KL
distances using the Wilcoxon Rank comparison. Table 5.1 shows the Wicoxon Rank
statistics comparing the KL distance between different models learnt using the different
approaches. An asterisk is used to denote significant p values. First of all we notice that
there are many significant values implying that the difference between models learnt
using the two different approaches are significant. The most important statistics are
those that show the models learnt with no calibration and only 500 cross-sectional data
points are significantly different from most other models (row 1), but when 1500 cross-
sectional data points are used the resulting model becomes much closer, only being
significantly different from the model learnt from 50 full time-series (row 4). However,
by calibrating these models we see a little improvement for 500 cross-sectional (CS)
data points but for 1500 datapoints calibrated with 20 time-series, there is no significant
difference between the models learnt from the full time-series. This implies that when
the CS sample size is large enough and the resulting PTS models are calibrated with a
relatively small number of real time-series, then a model can be learnt that is as good
as one learnt from all time-series data.
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Figure 5.4: Confidence Intervals for the KL Distance to the original model generating
the data for increasing sample sizes of cross-sectional data. i) with the non-calibrated
model (top) ii) with the model calibrated with 10 time-series (middle) and iii) with the
model calibrated with 20 time-series (bottom).
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Wilcoxon Rank cs500calib10 cs500calib20 cs1500nocalib cs1500calib10 cs1500calib20 csfull30 csfull50
cs500nocalib 0.196 0.047∗ 0.000∗ 0.000∗ 0.000∗ 0.000∗ 0.000∗
cs500calib10 - 0.455 0.062∗ 0.036∗ 0.000∗ 0.010∗ 0.000∗
cs500calib20 - - 0.077∗ 0.130 0.001∗ 0.023∗ 0.001∗
cs1500nocalib - - - 0.947 0.119 0.395 0.064∗
cs1500calib10 - - - - 0.052∗ 0.277 0.047∗
cs1500calib20 - - - - - 0.395 0.728
csfull30 - - - - - - 0.291
csfull50 - - - - - - -
Table 5.1: Wilcoxon Rank Comparison between KL distances to original (significant p values are marked with an asterisk).
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5.2.2 Calibrating PTS on Real Visual-Field Data
We now explore the effect of calibrating PTS using the real Visual Field time-series
data described earlier. As there is no knowledge of the true underlying model, we
firstly compare the KL distance between models that are repeatedly learnt from the
original 91 patient time-series (91 MTS VF DATA in Figure 5.5) in order to get an
idea of the general variance between models (MEAN VARIANCE) and to use this as
a base-line. Essentially, if a model can be generated using PTS approaches with a KL
distance that is not significantly greater than the general variance between different
builds of the model on the full data, then we can be confident that the PTS models are
of a suitably similar quality to those learnt from the full time-series.
Based on the consideration alone, the KL distance is calculated between a model
learnt from the sampled cross-section using the PTS approach (PTS on 91 SAMPLED
CS) and models learnt from the original 91 time-series. We then incrementally add a
number of randomly selected real time-series (RANDOM 10/20 MTS) to calibrate the
PTS model to see if this improves the KL distance.
Finally the KL distance is calculated between learning models using only the cali-
brated time-series to confirm that the PTS are indeed improving the resulting models.
The experiments are repeated 100 times to derive confidence intervals on the KL
distances. Figure 5.5 shows the overall scheme for all experiments and Figure 5.6
shows the results.
One observation is that the KL distance between models that have been learnt on
the full 91 time-series are in the region of 50 with a small confidence interval denoting
a relatively small variance from one model learning to the next. The models that are
91
Figure 5.5: The overall scheme for all calibration experiments.
learnt from the sampled cross-section using the PTS approach are impressively close
to the time-series models but distinctly higher in KL distance - approximate distance of
120 - (likely to be because we are lacking real temporal information). When 10 and 20
real time-series are used to calibrate the model, however, we see further improvement
in the KL distance resulting in models that are demonstrably closer to the models
learnt from all 91 time-series (mean distances of 100 and 80 for the models calibrated
with 10 and 20 series respectively). Finally, models that are learnt from using the
relatively small number of calibrating time-series only are clearly worse with much
higher distance and very large confidence intervals (mean distances of 290 and 210 for
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Figure 5.6: KL results for VF data with confidence intervals.
the 10 series and 20 series respectively).
To find out if these distances between models are significantly different, the
Wilcoxon rank test is used again. Table 5.2 shows the result of applying this test
to all combinations of models from Figure 5.4. An important thing to notice here is
that nearly all of the models are indeed significantly worse than the variation between
models learnt on the full longitudinal dataset (significant differences are marked with
an asterisk) except for the PTS model calibrated with 20 real time-series. This shows
that we can learn models that are as good as the natural variation between model build-
ing on the full longitudinal dataset by building PTS and calibrating with only 20 real
longitudinal samples. It can also be seen that many of the inferior models are similar
in terms of their distances except for the very worst models (learnt from only 10 time-
series) which are different from the superior models which are both PTS models that
have been calibrated.
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Mean variance Rand 10 Rand 20 PTS PTS Cal(10) PTS Cal(20)
Mean variance (full 91 MTS) - 0.000∗ 0.001∗ 0.001∗ 0.005∗ 0.011
Random 10 MTS - - 0.975 0.023 0.002∗ 0.001∗
Random 20 MTS - - - 0.042 0.014 0.010
PTS on 91 sampled CS - - - - 0.452 0.327
PTS Calibrated with 10 MTS - - - - - 0.773
PTS Calibrated with 20 MTS - - - - - -
Table 5.2: Wilcoxon Rank significance.
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5.3 Summary
In this chapter, we explored combining cross-sectional and longitudinal studies to build
more robust models by simply aggregating PTS with real time-series. Although the PT-
S approach alone does indeed learn very good models, by adding a small number of
real time-series it is possible to get models that are considerably closer to the models
learnt using all the time-series data that is available. We have shown that this is the
case with significance on both the simulated data (where we know the true underlying
model) and on VF data where we compare the distances to the general variation be-
tween models that are learnt from different repeats of the same model-building process
on the full longitudinal data.
Chapter 6
Conclusions and Future Work
This chapter draws together the conclusions reached based on the research presented in
this thesis. First, the main contributions are summarised, followed by a discussion of
the limitations of the research presented. Finally, potential avenues for further research
are presented, which are based on addressing the research limitations discussed in the
previous section, and extending the applicability of the techniques presented in this
thesis.
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6.1 Conclusions
This thesis documented the application of intelligent data analysis techniques for ex-
tracting information from time series generated by different diseases. The results p-
resented in this work relate to two major issues in this area of research: how clinical
variables interact as a disease progresses along the trajectories in the data; and how
to automatically identify different disease states along these trajectories, as well as
the transitions between them. A combination of simulated data and three real-world
biomedical cross-sectional datasets (Visual Field, Breast Cancer and Parkinson’s Dis-
ease) were used to demonstrate and validate the new approaches introduced here. Be-
ing able to model trajectories and the temporal aspect of disease from these datasets is
not trivial.
This thesis started with a review of previous and current research concerning the
application of machine learning for biomedical data analysis in Chapter 2. Clinical
trials were briefly discussed. The advantages and disadvantages of cross-sectional s-
tudies and longitudinal studies were also analysed. In the literature review, four typi-
cal models of classification and clustering were particularly examined in a biomedical
context. The research in this thesis focused on the use of sequence-building through
cross-sectional data (including trajectories with multiple endpoints).
The major work and achievements of this PhD thesis were presented in a logi-
cal sequence. Firstly, a formalisation of the pseudo time-series introduced by Tucker
[TGH10] was explored. In addition it was investigated how cross-sectional and longi-
tudinal data can both be better used to build more reliable models.
Different approaches to modelling trajectories through clinical data were identified
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and hidden Markov models implemented given that they are effective at dealing with
uncertainty and noise.
Secondly, an extension of the pseudo time-series approach, previously introduced
in [LST12], involving the implementation of relabelling the hidden state to identify in-
termediate stages in the disease process. The extended approach allows us to identify
the temporal nature of diseases, which is one of the major achievements of this study.
Other similar studies have previously explored the progression of disease through la-
tent variables, using longitudinal data. For example, studies that model non-stationary
time-series using state-space models have been developed that simultaneously fit dy-
namic time-series model parameters whilst identifying changes in the underlying state
([TL04], [RH10]). However, none of these attempt to exploit the smoothness of dis-
ease progression to fit trajectories through cross-sectional data, which is much more
abundant in clinical applications, in order to build time-series models and understand
progression. This is what we present here. It is clear that many of the longstanding
approaches as discussed in Chapter 3 to modelling disease progression are proving
inadequate to dealing with issues of uncertainty in the dynamic and measurement pro-
cesses and the ability to integrate cross-sectional studies with longitudinal studies.
Thirdly, as earlier, to demonstrate the effectiveness of the proposed approach, a
number of real disease studies were utilised. This allowed any characteristics of the
disease process that were discovered to be placed in a real medical context. Utilised
real disease studies included: glaucoma using visual field test data, breast cancer using
tumour image data and parkinson’s disease using speech data and discussed in Chapter
3. The rather promising results based on the approaches and techniques mentioned
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above are documented in Chapter 4. Regarding the glaucoma data, this study was able
to identify:
1. stable states with abnormal VF sensitivity and marked rim narrowing;
2. transitory states with moderate narrowing of rim;
3. subtle loss of retinal sensitivity in the central macula.
Those results fit well with current knowledge of the progression of glaucoma of which
initial symptoms can appear in the rim but not the visual field and vice versa.
By using the cancer data, the proposed approach also successfully identified:
1. stable states that reflect the benign and malignant tumour states;
2. an intermediate state that is characterised by a subset of the symptoms of malig-
nant tumours.
With the Parkinson’s disease data, a transitory state was discovered which has
certain characteristics of Parkinsonism despite being pre-classified as symptoms of
controls.
Chapter 4 empirically demonstrated the advantages of applying the proposed rela-
belling algorithm, to pseudo time-series. It highlights how key intermediate stages of
disease can be identified and evaluated using simulated data (with complex multiple
disease stages endpoints), and real clinical data from three very different diseases.
Finally, due to identified limitations of using cross-sectional data alone to build
these models (the fact that no genuine time-stamps have been used to infer the models),
in Chapter 5, we investigated the effect of incorporating genuine longitudinal data into
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the pseudo temporal models in order to calibrate the models. This work particularly
examined how to best balance the utilisation of cross-sectional and longitudinal data
in order to minimise the cost of longitudinal data collection, a process which is quite
expensive. This is essentially a matter of integrating cross-sectional and longitudinal
data. The overall aim is to exploit the advantages of both types of studies - population
diversity of cross-sectional data and temporal information in longitudinal data. We
explored to what degree pseudo time-series models, learnt from building trajectories
through a cross-sectional study, can be calibrated by a relatively small number of real
time-series data form a clinical longitudinal study. The results show that almost all
models are significantly different from the general variance when learning the model
from the full 91 time-series. The only model that is not significantly different at the
1% level is the model that is learnt from the PTS and calibrated with 20 time-series.
6.2 Caveats and Future Work
There are a number of limitations in the research presented in this thesis. Firstly, the
techniques presented have only been tested with the structure imposed by the HMM
architecture. The utilised models are intended for stationary processes meaning that
parameters and relations between variables are considered stable over time. However,
extension of the techniques for the stationary HMMs has provided a solid foundation
from which they can be further extended for modelling changing structure within a
clinical time-series.
Secondly, when calibrating the pseudo time-series models, a simple process of
concatenating the datasets was used. This may cause some difficulties in balancing
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the influence of the pseudo time-series and the calibrating time-series. In other words,
if there are too many pseudo time-series, the relatively smaller number of calibrating
time-series may have little effect. Though this was not the case in our experiments,
another more structured approach to combining them could be explored such as tak-
ing the pseudo time-series model as a prior model and updating it within a Bayesian
framework using the calibrating data. That is, a suitable balance could be identified
between the two sources of data
Additionally, for the simulated data, the number of variables was kept very small.
Therefore, the applicability of the proposed techniques to a broader range of types of
data and larger networks has not been considered. However, the utilisation of mod-
els such as dynamic Bayesian networks for data with more variables would be worth
exploring.
As part of further work, the modelling techniques could be extended in a number of
ways. As discussed in chapter 4, the techniques presented in this thesis have only been
used with HMMs, although modelling temporal behaviour plays an important role in i-
dentifying key stages in a disease process. In particular, to improve the directionality of
the learnt interactions, temporal information may be incorporated through time nodes
and DBNs. As already mentioned in Section 3.4.1, a limitation of HMMs, concerns
the fact that parameters and relations between variables cannot change over time. In
many medical contexts, however, dependency relations between variables can change
over time. For example in glaucoma, the Optic Nerve Head, which carries the visual
functional signal, structurally changes during the progression of the disease, resulting
in non-stationary series [YD03]. To overcome the stationarity in time series modelling
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with graphical models, non-stationary DBNs have been recently introduced ([GH09],
[RH10], [TH05]), which attempt to learn when the changes in structure occur.
Furthermore, Chapter 5 of this thesis explored the combination of data from cross-
sectional and longitudinal studies to build more robust models of disease progression,
by simply aggregating PTS with real time-series. However, some of the methods de-
scribed in this thesis can be further extended that could be explored would be to take
a Bayesian approach that uses informative priors [CS00]. By adopting a Bayesian ap-
proach using informative priors to integration, cross-sectional studies can be used to
learn prior models [CS00]. This can be performed either directly on the data, resulting
in static Bayesian networks, or via the pseudo time-series approach, described in this
thesis, to produce DBNs models.
These priors can then be updated with the real time-series from longitudinal studies
in order to ‘calibrate’ the temporal models. For example, The PTS models could be
built and used as priors which then could be updated with the real time-series. In this
way, we could control the influence of each type of data more carefully. If we have
more reasons to trust the fidelity of the cross-sectional data more, we could bias the
Bayesian updating process to the prior models, whereas if we want the longitudinal
data to have more influence we could weaken the effect of the priors. This approach
overcomes some of the issues concerning the models generated from the sequence
reconstruction models such as the lack of genuine temporal information.
Integrating both longitudinal and cross-sectional data offers the advantage of mod-
elling diverse populations, which incorporate samples of all stages of disease, whilst
also encoding the genuine temporal characteristics of disease processes. The models
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explored and extended in this thesis make important steps in this integration through
the use of pseudo-temporal resampling and the produced results demonstrate their a-
bility to identify important stages in disease progression.
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Appendix A
A.1 Math Notation
C defined classes labels
Ci = 0 sample i corresponds to a healthy case
Ci = 1 sample i corresponds to a disease case
D a real valued cross-sectional data
D(i) ith row of matrix D
Dk a distance matrix
dij shortest path from i to j
G weighted graph
h hidden states
k number of pseudo time-series
m the number of samples (patients)
n the number of variables in the clinical test data
P a set of pseudo time pseudo time-series
Pa(xi) the parent set of a node Xi
Q a continuous vector of unknown parameters
T sample size
wij weight matrix
X t the variables in the time series
X observed data
Z a set of unknown latent variables
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A.2 Abbreviation
ARHMM Auto-regressive hidden Markov model
ADTree Alternating Decision Tree
BC Breast Cancer
BN Bayesian Network
CPD Conditional Probability Distribution
DAG Directed Acyclic Graph
DBN Dynamic Bayesian Network
DTree Decision Tree
EM Expectation Maximisation
HMM hidden Markov model
HRT Heidelberg Retina Tomography
KL Kulbaeck Leibler
ML Machine Learning
MNN Multilayer Neural Network
MPTS Multivariate Pseudo Time-Series
MTS Multivariate Time-Series
NBs Naı¨ve Bayes
NN Neural Network
PD Parkinson’s disease
PTS Pseudo Time-Series
TBS Temporal Bootstrap
VF Visual Field
